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Multiple Sclerosis (MS) is an incurable disease which is commonly associated with 
psychological complications. Previous research by Hayter and colleagues found that in 
patients with MS, health anxiety (HA) can account for part the variance in quality of life 
(QoL) independent of any physical and cognitive impairment caused by the disease and 
that MS patients with health anxiety perceived their (intact) physical and cognitive 
performance as impaired relative to MS patients without health anxiety, attributing the 
impairment to MS. The findings suggest that such misperceptions might be useful targets in 
the treatment of health anxiety in MS using adapted cognitive behavioural therapy (CBT). 
The first of two studies presented here sought to replicate the findings from Hayter et al. 
before a second presents the findings from a brief case series of treatment for HA using 
CBT. In Study 1, twenty participants with Relapsing and Remitting MS were screened for 
HA and assigned to either a high or low HA group. Participants then completed 
assessment of cognitive and physical functioning before rating their performance on these 
tasks. Measures of QoL, mood and physical disability were then completed. Four 
participants in the high HA group subsequently received six sessions of CBT using a 
consecutive AB case series in Study 2. Study 1 replicated the main findings from the earlier 
study. In Study 2, three of the four patients who received treatment showed substantial 
improvements in HA and mood and all showed improvement in QoL. Given the high rates 
of HA in MS patients and its impact on QoL, this case series suggests a brief CBT 
intervention could significantly improve patients’ wellbeing. The findings pave the way for 
larger, controlled studies into the effectiveness of CBT for health anxiety in MS.     
Service Improvement Project 
Background: Early diagnosis of neurodevelopmental conditions such as Autism Spectrum 
Disorders (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) in children are 
enshrined in national UK policy, as is ensuring that parents’/carers’ views shape service 
delivery. Aim: The present study attempted to measure adherence to service guidelines of a 
neurodevelopmental disorders assessment clinic within a Child and Adolescent Mental 
Health Service (CAMHS) to identify service needs. It also assessed parents’/carers’ 
satisfaction with the service and what information should be included in a patient 
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information leaflet. Method: An audit of cases referred during 2012 -2013 plus a postal 
survey of parents/carers of children referred during the audit period. Results:  The service 
was mostly compliant with NICE guidelines but quantifying this was difficult under its 
current record keeping. While satisfied with the clinic’s service, the main concern of 
parents/carers was the length of time the assessment process took. Conclusions: Adoption 
of NICE audit tools would help document compliance with guidelines. A patient 
information leaflet might help manage parents’ expectations about the time the assessment 
process takes. 
Literature Review 
This review considers the closely related concepts of rumination and worry; examining 
their role in insomnia and chronic pain.  Worry has been seen for many years as a major 
contributor to insomnia but only recently has attention been paid to the role of rumination. 
Similarly, worry and rumination have both been implicated in the maintenance of distress 
in chronic pain. However, across these two diagnostic categories (and the wider research 
literature) definitions of worry and rumination vary and are often used interchangeably. 
This review considers the research literature on rumination/worry in relation to insomnia, 
chronic pain and insomnia that occurs alongside chronic pain (pain-related insomnia). 
The empirical findings to date suggest patterns of repetitive negative thinking characterise 
both worry and rumination, but the content of the thinking may be distinct, opening the 
way for the application of transdiagnostic approaches.  It suggests cognitive behavioural 
approaches to treating pain-related insomnia can be improved by incorporating elements 
which have been successful elsewhere in allowing people to manage repetitive negative 
thinking. Assessment of these targeted treatments in future research should lead to a 
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This review considers the closely related concepts of rumination and worry; examining 
their role in insomnia and chronic pain.  Worry has been seen for many years as a major 
contributor to insomnia but only recently has attention been paid to the role of rumination. 
Similarly, worry and rumination have both been implicated in the maintenance of distress 
in chronic pain. However, across these two diagnostic categories (and the wider research 
literature) definitions of worry and rumination vary and are often used interchangeably. 
This review considers the research literature on rumination/worry in relation to insomnia, 
chronic pain and insomnia that occurs alongside chronic pain (pain-related insomnia). 
The empirical findings to date suggest patterns of repetitive negative thinking characterise 
both worry and rumination, but the content of the thinking may be distinct, opening the 
way for the application of transdiagnostic approaches.  It suggests cognitive behavioural 
approaches to treating pain-related insomnia can be improved by incorporating elements 
which have been successful elsewhere in allowing people to manage repetitive negative 
thinking. Assessment of these targeted treatments in future research should lead to a 





1.2 OVERVIEW  
“Twelve years of insomnia research led us to worry” 
(Borkovec, Robinson, Pruzinsky, & DePree, 1983, p. 9) 
It almost seems self-evident that with chronic pain comes difficulty sleeping. By the same 
token, sleeplessness would seem likely to, at the very least, reduce the bearability of 
chronic pain and may even increase its perceived severity. Indeed, over the years in 
patients with chronic pain, sleep difficulties were labelled “secondary” to highlight the 
etiological role of pain. But over the last decade or so research is starting to suggest that 
the relationship between the two conditions may be neither linear nor unidirectional 
(Smith, Perlis, Smith, Giles, & Carmody, 2000; Tang, Goodchild, & Salkovskis, 2012b). 
This has been recognised in the Diagnostic and Statistics Manual of Mental Disorders-5
th
 
Edition (DSM 5) which removed the primary/secondary distinction in insomnia disorder so 
that its definition better captures the bi-directional nature of insomnia with other medical 
or mental health problems (APA, 2013). So rather than insomnia secondary to chronic 
pain, the insomnia disorder is classified as “in addition to” chronic pain. Even so, with 
insomnia and chronic pain it is yet to be established how these two conditions interact and 
the mechanisms by which one condition maintains and/or exacerbates the other. Some 
authors have used the term ‘pain-related insomnia’ to capture the interactive nature of 
these conditions and will be the term used here (Tang, Goodchild, Hester, & Salkovskis, 
2012a). The present review considers chronic pain-related insomnia from the perspective 
of a potential common cognitive mechanism in both chronic pain and insomnia: repetitive 
negative thinking in the form of rumination and/or worry. While a number of cognitive 
processes involved in the maintenance of insomnia and chronic pain have been identified, 
the focus here is on rumination and worry because while they have received a lot of 
attention over the years, an integrative model that explains these processes in chronic pain-
related insomnia remains elusive.  
It has long been known that worry and rumination play a major role in insomnia 
(Borkovec, Ray, & Stober, 1998; Carney, Harris, Moss, & Edinger, 2010; Harvey, 2002; 
Harvey, Tang, & Browning, 2005) but for many years the terms were used interchangeably 
and only recently have researchers begun to delineate the two as potentially playing similar 
but distinct roles (Carney, Edinger, Meyer, Lindman, & Istre, 2006; Carney et al., 2010; 
Thomsen, Yung Mehlsen, Christensen, & Zachariae, 2003). Similarly, in the chronic pain 
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literature, worry (Eccleston & Crombez, 2007) and rumination (Sullivan, Bishop, & Pivik, 
1995) have both been linked to increased distress. However, definitions of worry and 
rumination vary within the research on chronic pain and insomnia and across the literature 
more generally (Watkins, 2008). In this review, the aim is to synthesise the research 
literature on rumination/worry in relation to chronic pain-related insomnia. It will begin by 
first considering definitions of worry and rumination in the literature before considering 
research dating back to the 1970’s that has attempted to demonstrate their role in the 
maintenance of insomnia. This literature came together in a cognitive model of insomnia 
developed by Alison Harvey (2002). While the model proposed a clear role for worry and 
rumination, it and the literature more generally, had not clearly specified whether they 
played the same or distinct roles in insomnia’s maintenance. Hence the review then 
considers recent research that has attempted to differentiate the role of the two processes in 
insomnia but acknowledges that the difference between them may be one of content rather 
than process. While worry and rumination have been shown to be important in insomnia, it 
is unclear whether they have a similar function in chronic pain in general and pain-related 
insomnia in particular. These two questions are considered before moving towards 
considering worry and rumination in terms of transdiagnostic approaches and the utility of 
classifying them both as a process of Repetitive Negative Thinking (RNT) that differ only 
in the content to which they relate to. A mechanism by which RNT might then lead to the 
maintenance of both insomnia and pain-related insomnia is proposed within the context of 
Harvey’s (2002) cognitive model before considering the implications of such a mechanism 
for the treatment of pain-related insomnia. The review concludes by suggesting that worry 
and rumination in insomnia and pain-related insomnia can best be conceptualised as RNT. 
In doing so, it aids the development of specific and targeted treatments in the future that 
can help reduce the distress of patients with chronic pain who also have difficulty sleeping.  
1.3 DEFINITIONS OF WORRY AND RUMINATION 
In Response Styles theory, Nolen-Hoeksema and colleagues describe rumination as, 
“repetitively and passively focusing on symptoms of distress and on the possible causes 
and consequences of these symptoms. Rumination does not lead to active problem solving 
to change circumstances surrounding these symptoms.” (Nolen-Hoeksema, Wisco & 
Lyubomirsky, (2008), p. 400).  They go on to state that rumination is repeatedly thinking 
about problems and emotions, rather than it having any specific content. Worry on the 
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other hand, is defined by Borkovec et al. as “... a chain of thoughts and images, negatively 
affect laden and relatively uncontrollable. The worry process represents an attempt to 
engage in mental problem solving on an issue whose  outcome is uncertain but contains the 
possibility of one or more negative outcomes” (1983, p. 10). Hence rumination is seen as 
passively focusing on what is causing the current situation or condition and its symptoms 
whereas worry focuses on the potential negative outcomes and actively tries to find 
solutions to the problem: worry is future oriented, rumination focuses on the past. Thus 
worry and rumination are seen as repetitive cognitive processes but vary in mood and 
content (Segerstrom, Tsao, Alden, & Craske, 2000). Worry is associated with anxious 
states; its future oriented focus means the individual is likely to attempt to anticipate future 
threats, often catastrophising about what will happen. So for example, they may worry that 
their anxiety will make it difficult for them to get to sleep later that night and lead to 
reduced functioning the next day. Rumination on the other hand is a response to the 
symptoms of low mood states and the possible causes of dysphoric mood (Nolen-
Hoeksema, 1991). So the individual with insomnia may be focussing on why they are 
feeling tired during the day and attribute it to the poor sleep the night before. However, 
Martin and Tesser (1996) define rumination as a form of repetitive thought that is related 
to subjective goals and concerns. In this definition, rumination can be helpful or unhelpful 
depending on whether it allows a person to move towards their goals. Hence it does not 
necessarily have to be related to distress. While the authors above have attempted to 
differentiate worry and rumination in general terms, as will be shown, this has not always 
happened when studied in the context of insomnia or pain-related insomnia. 
1.4 THE PROBLEM OF INSOMNIA 
Insomnia is a problem for a large proportion of adults, especially for those suffering 
chronic pain. Between 10 – 16 percent of adults report not getting enough sleep (Ancoli-
Israel & Roth, 1999; Gallup, 2002) with approximately 6 percent meeting diagnostic 
criteria for insomnia (Ohayon, 2002). The DSM-5 defines insomnia disorder as “difficulty 
initiating and maintaining sleep (experiencing frequent awakenings and difficulty returning 
to sleep once awake) or waking up too early and being unable to fall back asleep” (APA, 
2013). In addition, to meet DSM criteria, the sleep disturbance should also cause clinically 
significant distress, occur on at least 3 nights per week and have lasted for over 3 months. 
While insomnia can occur in isolation, for the majority it occurs alongside medical and/or 
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psychiatric disorders (Ohayon & Roth, 2001) with rates of insomnia ranging from 16-82 
percent (Katz & McHorney, 1998; Smith, Huang, & Manber, 2005; Smith et al., 2000).  
While it is acknowledged that a range of physiological and behavioural factors are 
implicated in the development and maintenance of insomnia, there has been a large body 
of research implicating cognitive factors.  
1.5 COGNITIVE FACTORS IN INSOMNIA 
In a historical review covering a broad range of cognitive factors, Harvey et al. (2005) note 
that as early as 1970 authors were implicating worry and rumination as important elements 
of insomnia. Storms and Nisbett (1970) hypothesised that worry/rumination about not 
getting to sleep led to increased arousal and thus increased sleep onset latencies. They gave 
placebo tablets to patients with insomnia telling half of them that the tablets would cause 
arousal and the other half relaxation. The finding that those given the ‘arousal’ tablet fell 
asleep sooner was seen as being due to these patients attributing their arousal to the tablet 
and thus reducing anxiety.  
In 1980, Lichstein and Rosenthal asked 296 people with insomnia whether their problems 
sleeping were due to somatic or cognitive arousal. Participants were 10 times more likely 
to state that cognitive arousal was a cause of their insomnia compared to somatic arousal. 
Similarly, Espie et al. (1989) administered the Sleep Disturbance Questionnaire to 
participants with insomnia and found they were much more likely to give higher ratings to 
statements such as, “My mind keeps turning things over” and, “I am unable to empty my 
mind”, suggesting they felt that worry was a major reason for their sleep problems (Espie, 
Brooks and Lindsay, 1989).  
In a study that attempted to directly manipulate worry, Gross and Borkovec (1982) told a 
group of good sleepers that they would have to give a speech after an afternoon nap. 
Participants who were not told they had to give a speech fell asleep faster and this was 
attributed to them not worrying about having to give a speech. However, Harvey et al. 
(2005) note that the authors did not directly check whether having to give a speech actually 
increased worry in participants. While a number of studies such as the one by Gross and 
Borkovec have shown a relationship between cognitive factors and sleep onset latency, 
others have mixed findings. For example, Van Egren et al. (1983) found that while 
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worrying about getting to sleep did correlate positively with self-reported estimates, it did 
not correlate with objective estimates based on polysomnography.  
In the early 1990s researchers began exploring the content of worry in insomnia. Watts, 
Coyle and East (1994) and Fichten et al. (1998) found that the content of thought prior to 
sleep focussed on sleep itself, planning as well as recent and long-term concerns. Similarly, 
in a study by Wicklow and Espie (2000) they found an association between cognitive 
factors and objective measures of sleep onset latency. In their study they gave participants 
a voice-activated recorder and told them to say out loud any thoughts they were having 
while trying to get to sleep. The authors then subjected the transcribed tapes to content 
analysis to reveal eight categories of pre-sleep thought. These included: 
rehearsal/planning/problem solving; sleep and its consequences (ease/difficulty of falling 
asleep, consequences of not sleeping); reflection on quality of thoughts (mind buzzing, 
thoughts rushing); arousal status (pre-occupation with physical tiredness); external noise; 
autonomic experiences (thinking about heart rate, itching, restlessness); procedural factors 
(relating to the research project itself) and rising from bed (thinking about getting up, 
turning on the light). However, even though Wicklow and Espie and others were beginning 
to examine the content of pre-sleep thought, they still make no distinction here between 
whether the process constituted a distinction between worry or rumination. It was 
consideration of the process by which worry and rumination maintain insomnia that led 
Alison Harvey to develop her cognitive model (2002). 
1.6 A COGNITIVE MODEL OF INSOMNIA 
It was the development of robust cognitive models for a number of other psychological 
disorders (e.g., Ehlers and Clark (2000); Salkovskis, Clark, and Gelder (1996)) as well as 
the findings from the research discussed above that led Harvey (2002) to propose a 
cognitive model of  the maintenance of insomnia (see Figure 1.1). In her model, insomnia 
is seen as a 24 hour a day problem where “negatively toned cognitive activity” (p.871) is 
focussed on not getting enough sleep and the impact this will have on the next day’s 
functioning such as daytime fatigue, poor concentration etc. In the model, rumination and 
worry trigger autonomic arousal leading to a state of anxiety. Due to their anxious state the 
individuals attention becomes focussed on threat related cues both internally (body 
sensations) and externally (the bedroom environment) that tell the person they are not 
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getting enough sleep and/or that during the day they are not performing well or are feeling 
fatigued. Because high arousal states lead to a narrowing of attention towards threat related 
cues, these cues are more likely to be noticed (Clark, 1999). When the individual detects 
such sleep-related threat it gives rise to further worry and rumination and further increases 
in arousal and distress. Harvey then proposes that the anxious state and attentional bias 
make the individual think they have had less sleep than they actually did and that daytime 
functioning was much worse than it really was. These distortions then feedback into 
worry/rumination about the potentially long term consequences of reduced sleep such as, 
“I’m going to get ill” or, “I will lose my job” and hence the vicious cycle continues. 
Erroneous beliefs about sleep, such as overestimating the actual amount of sleep adults 
need to survive, also exacerbate worry and rumination as do safety seeking behaviours. In 
Harvey’s model these safety seeking behaviours might include spending longer in bed 
trying to sleep, trying to control their thinking, or drinking caffeine during the day (to stay 
awake) and alcohol at night (to get to sleep) (see Morin & Barlow, 1993; Perlis, Giles, 
Mendelson, Bootzin, & Wyatt, 1997). The effects of these cognitive and behavioural 
processes are to “trap the individual into becoming progressively more absorbed by and 
anxious about the sleep problem” (Harvey, 2002, p. 873). Worry and rumination can be 
seen as subcomponents of negatively toned cognitive activity that plays a central role in 
Harvey’s model but it is still unclear the extent to which these are distinct or overlapping 






Figure 1.1: A cognitive model of the maintenance of insomnia (taken from Harvey, 2002) 
1.7 DISTINGUISHING WORRY AND RUMINATION IN 
INSOMNIA 
While worry has been shown to play a key role in the maintenance of insomnia, as shown 
in the studies reviewed above, only a handful have specifically focussed on the role played 
by rumination. Carney et al. (2006) argue that this is due in part to insomnia researchers 
generally using the terms ‘rumination’ and ‘worry’ interchangeably and in part using 
measures to assess worry that also include items on rumination: making it difficult to 
distinguish between the two. One study that did specifically focus on rumination in 
insomnia was Thomsen et al. (2003). They used a measure that encompassed a broader 
definition of rumination than those that focus on depressive symptoms (e.g., the 
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Rumination Response Scale, (Nolen-Hoeksema, 1991)). In doing so Thomsen et al. (2003) 
found that rumination was correlated with general sleep quality, sleep-onset latencies, and 
sleep disturbances. They took this finding to mean that worry and rumination 
independently contribute to sleep quality. In another study, Carney et al. (2006) used a 
symptom focussed scale of rumination and found that those who had trouble sleeping 
repetitively think about the causes of their fatigue, achiness, and concentration difficulties 
to a greater extent than good sleepers.  
However, both the above studies were conducted on non-clinical samples which led 
Carney et al. (2010) to study whether rumination, separate to worry, impacts on subjective 
measures of sleep quality in people with clinical levels of insomnia. They administered the 
symptom focussed rumination subscale of the RSQ as well as the PSWQ to participants 
with a clinical diagnosis of insomnia. They found that worry and rumination were 
significantly correlated and that rumination had a significant correlation with several 
subjective measures of sleep quality. Furthermore, while participants high and low in 
rumination differed on measures of sleep onset, sleep quality and waking after sleep onset, 
the effect sizes were all small and the authors did not use any objective measures of sleep 
such a polysomnography or actigraphy. Finally, the cross-sectional design means the 
authors were not able to say whether rumination plays any causal role in insomnia. 
However, notwithstanding the limitations of the study, Carney et al. were able to highlight 
the importance of rumination in insomnia that is focussed on symptoms and differentiate it 
from worry. Given the correlation between worry and rumination in their study, the 
difference they found between their measures may actually be one of content rather than 
process. 
In summary, the insomnia research suggests that both worry and rumination have an 
important role in the maintenance of insomnia. However, worry and rumination appear to 
share a repetitive thinking element but differ in content: rumination is focussed on 
symptoms of insomnia and their cause (Carney et al., 2006) while worry is focussed on the 
consequences of sleeplessness (Wicklow & Espie, 2000). However, it is not clear whether 
a similar distinction can be made between worry and rumination in pain-related insomnia. 
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1.8 THE PROBLEM OF CHRONIC PAIN AND RELATED 
INSOMNIA 
The DSM-5 is unclear about the definition of chronic pain due to the complexity of 
psychological and medical factors that contribute to a person’s experience of it. Hence 
some individuals can be diagnosed with somatic symptom disorder with predominant pain, 
while others an adjustment disorder (APA, 2013). In patients suffering from chronic long-
standing pain, between 50 and 88 percent will also suffer from insomnia (Atkinson, 
Ancoli-Israel, Slater, Garfin, & Gillin, 1988; Morin, Gibson, & Wade, 1998; Smith et al., 
2000; Tang, Wright, & Salkovskis, 2007); and insomnia is seen by some as chronic pain’s 
most disabling side effect (Follick, Smith, & Ahern, 1985). Insomnia used to be classified 
according to whether it was primary or secondary (i.e., attributable to a medical, 
psychiatric or environmental cause) (APA, 1994). Hence by reducing the symptoms of 
chronic pain, insomnia would be alleviated. However, insomnia can still continue for many 
patients even after adequate pain control (Ashworth, Burke, & McCracken, 2008). 
Furthermore, for insomnia to be “secondary” it should get worse when the pain becomes 
more severe. Smith et al. (2005) argue that in clinical settings, distinguishing the cause of 
insomnia’s severity is often impossible due to it being related to multiple medical, 
behavioural and psychological factors.  
Cross-sectional research suggests that sleep problems are linked to the severity of pain 
reported by patients and reductions in pain thresholds (Moldofsky & Scarisbrick, 1976; 
Morin et al., 1998; Smith et al., 2000; Wilson, Watson, & Currie, 1998) and pain severity 
negatively impacts on sleep onset, number or awakenings during sleep, sleep duration and 
restful sleep (Morin et al., 1998; Nicassio, Moxham, Schuman, & Gevirtz, 2002; Pilowsky, 
Crettenden, & Townley, 1985; Smith, Perlis, Carmody, Smith, & Giles, 2001; Wilson, 
Eriksson, D'Eon, Mikail, & Emery, 2002). Longitudinal studies also show similar results 
(Affleck, Urrows, Tennen, Higgins, & Abeles, 1996; Drewes et al., 2000). However, as 
stated above, insomnia can persist even when pain is controlled; leading researchers to 
examine cognitive-behavioural factors that affect chronic pain such as inactivity, low 
mood, and pre-sleep worry/rumination and their role in exacerbating the poor sleep 
experienced by these patients (Morin, Kowatch, & Wade, 1989; Pilowsky et al., 1985; 
Raymond, Nielsen, Lavigne, Manzini, & Choinière, 2001; Smith et al., 2000). While the 
exact relationship between sleep and chronic pain is still unclear, the research above points 
to a vicious cycle developing where poor sleep leads to increased pain sensitivity which 
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then negatively impacts on insomnia (Pigeon et al., 2012; Tang et al., 2012b). This has led 
to the view that in chronic pain patients, the “co-morbid” insomnia should be treated as a 
distinct problem to alleviate distress (NIH, 2005). Hence psychological models and 
treatment methods for insomnia separate from any other condition are increasingly being 
seen as having utility for insomnia in chronic pain. However, given the lack of clarity over 
the relationship between insomnia and chronic pain, treatment approaches are likely to be 
improved if they incorporate a more sophisticated understanding of the processes involved. 
Hence the review next considers the cognitive processes (including rumination and worry) 
that contribute to maintenance of distress first in chronic pain and then in pain-related 
insomnia.  
1.9 COGNITIVE FACTORS IN THE MAINTENANCE OF 
CHRONIC PAIN 
According to Eccleston and Crombez (2007), “Pain is an ideal habitat for worry to 
flourish” (p.234). This is because pain is the body’s alarm system that alerts it to injury and 
to therefore take action. When the pain is brief, the person acts in an attempt to relieve the 
pain or escape what is causing the pain. However, when the pain is chronic, as in low back 
pain, the pain persists even after repeated attempts to relieve it. In this scenario, research 
has shown that patients worry about what has caused the pain and whether it will lead to 
long term disability if the cause is not treated (Moore, Von Korff, Cherkin, Saunders, & 
Lorig, 2000). In chronic pain, the erroneous beliefs and catastrophising that the pain is the 
result of physical injury can lead to fear about pain and avoidance of activity that might 
lead to pain - similar to forms of phobic behaviour (Leeuw et al., 2007). Based on 
observations that worry is a form of attempted problem solving, Eccleston and Crombez 
(2007) suggest that in chronic pain, problem solving is misdirected. In their cognitive 
model (see Figure 1.2) the individual experiencing chronic pain worries about its causes 
and its consequences but frames the pain as a problem caused by physical injury that needs 
to be solved through attempts to remove the pain. When, as in chronic pain, these attempts 
often fail, the model posits a ‘perseverance loop’ where the failure to solve the problem 
leads to further worry by the individual. Importantly, the worry increases attempts at trying 
to solve the problem but this increased effort only narrows and restricts their formulations 
of the problem, leading to repetition of the same failed attempts at pain relief. According to 
their model, only by reframing the problem as other than a biomedical one can the 
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individual head towards solutions that reduce their suffering. Hence cognitive therapeutic 
approaches to help the patient reassess the usefulness of worry or challenge their 
catastrophic thinking can help them to move away from the unachievable goal of pain 
relief towards living a meaningful life in the presence of pain.  
Similar to the literature on insomnia, the role of rumination has not always been clearly 
defined in chronic pain. It is either seen as similar to worry (Moore et al., 2000) or as a 
subcomponent of catastrophising (Buenaver et al., 2012; Turner & Aaron, 2001). Sullivan 
et al. (1995) developed the Pain Catastrophizing Scale that included rumination, 
magnification and helplessness as subcomponents. Using this scale Sullivan, Stanish, 
Waite, Sullivan, and Tripp (1998) found that the rumination subscale was the strongest 
predictor of pain in their sample. Melanie Edwards and colleagues (Edwards, Tang, 
Wright, Salkovskis, & Timberlake, 2011) suggest that rumination may be triggered by 
catastrophic thinking and appears to be related to pain intensity and sleeplessness. 
However, their definition of rumination includes problem solving as a subcomponent in 
contradiction to more traditional definitions of rumination as a passive process of thinking 
about causes and symptoms (Nolen-Hoeksema et al., 2008). In an unpublished paper on 
their development of a new measure of rumination in chronic pain, Edwards et al. 
(unpublished) found that in chronic pain patients, rumination about their pain was 
positively correlated with pain intensity to a greater extent than in pain free controls. 
Furthermore their findings suggest that rumination can be distinguished not only from 
catastrophising but also worry (as assessed using the PSWQ) in chronic pain.  
The research literature reviewed above suggests a role for both rumination and worry in the 
amplification of distress in chronic pain. In a similar way to insomnia, both rumination and 
worry can be conceptualised as a repetitive negative thought process that only differs in its 
content. What remains unclear in the chronic pain literature is whether worry and 
rumination play distinct roles in sleep disturbance. As we have already seen, worry and 
rumination are both implicated in cognitive arousal in insomnia disorder; hence the review 
now explores the evidence regarding their impact in pain related insomnia – an area that 





















Figure 1.2: A cognitive model of chronic pain (taken from Eccleston and Crombez (2007)) 
1.10 WORRY AND RUMINATION IN PAIN-RELATED INSOMNIA 
Pain has been linked to sleep difficulties (Moldofsky, Scarisbrick, England, & Smythe, 
1975; Pilowsky et al., 1985; Smith & Haythornthwaite, 2004) but sleep disturbance has 
also been found to directly predict subsequent pain (Edwards et al., 2009; Edwards, 
Almeida, Klick, Haythornthwaite, & Smith, 2008; Quartana, Wickwire, Klick, Grace, & 
Smith, 2010). Hence it seems appropriate to focus on factors other than pain itself that 
contribute to pain-related insomnia. Smith et al. (2000) found that cognitive arousal best 
predicted sleep quality in chronic pain patients over and above somatic arousal, daily 
activity levels, depressive symptoms and severity of pain. In a further study Smith et al. 
(2001) asked chronic pain patients to tape record their pre-sleep thoughts over a seven 
night period. They found that participants with chronic pain had frequent catastrophic 
thoughts about their pain but these were not significantly more frequent than negative sleep 
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related thoughts or thoughts about the bedroom environment. While pain related thoughts 
predicted sleep onset latency, the frequency of these thoughts was not related to pain 
severity. They took this to confirm their hypothesis that cognitive arousal due to 
rumination about pain and the consequences of the pain as well as negative thoughts about 
sleep were contributing to their problems in getting to sleep. While they give no formal 
definition of rumination, their findings suggest that patients in their sample were focussing 
on the symptoms, causes and consequence of their pain in line with the earlier definitions 
of rumination (Nolen-Hoeksema, 1991). Smith et al. suggest that while rumination is 
implicated in both insomnia and pain-related insomnia, the content of their ruminations 
includes thoughts about pain and its consequences. In insomnia they ruminate about the 
causes and consequences of not sleeping (Van Egeren, Haynes, Franzen, & Hamilton, 
1983), in chronic pain they additionally ruminate about pain and the consequences of their 
pain. These thoughts then increase cognitive arousal and thus impede initiation and 
maintenance of sleep.  
Tang et al. (2012a) compared patients with insomnia and pain-related insomnia across a 
range of variables. They found that the insomnia group tended to worry more than the 
pain-related insomnia group (as assessed by the PSQW). However, even in the pain-related 
group, mean worry scores indicated levels of worry associated with generalised anxiety 
disorder. The similarities between the groups on measures known to affect insomnia (such 
as sleep related anxiety, somatic arousal etc.) suggest that similar cognitive behavioural 
processes were at work across these groups, suggesting the use of Cognitive-Behavioural 
Therapeutic approaches that have been successful in treating insomnia can be successfully 
applied to the treatment of pain-related insomnia. Unfortunately, Tang et al. did not include 
a measure of rumination in their study, so as yet it is still unclear whether these two groups 
differ in their tendency to ruminate. Also, while Tang et al. found that patients with pain-
related insomnia do worry, it is not clear what the content of the worry is. However, given 
the finding of Smith et al. (2001) that in pain-related insomnia the content of rumination is 
focussed on pain, one could speculate that the content of worry in pain-related insomnia 
would also be focussed on pain. Further research is needed to clarify this point.  
Buenaver et al. (2012) used the PCS to assess the effects of pain catastrophising and sleep 
disturbance on pain severity. They theorised that pain catastrophising not only has a direct 
effect on pain but also indirect effects on pain through disrupting sleep due to the effect of 
reduced sleep on pain intensity (Edwards et al., 2008). They found that only the rumination 
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subcomponent of the PCS predicted indirect effects on clinical pain through rumination’s 
association with sleep difficulties. Their results are consistent with previous findings by 
Smith et al. (2001) that increased thinking about pain prior to sleep onset leads to reduced 
sleep onset latencies in chronic pain patients. These sleep difficulties then have a negative 
impact on pain experience.    
In summary, it would appear that both worry and rumination play a role in the maintenance 
of pain-related insomnia via a process of repetitive negative thought. While the same 
processes involved in the maintenance of insomnia disorder appear to be maintaining the 
sleep disturbance in pain-related insomnia, the content of the thought process also includes 
pain and its consequences as opposed to just negative thoughts about sleep. Given these 
findings the review now considers whether this repetitive negative thinking process is best 
conceptualised in terms of a transdiagnostic approach.   
1.11 TOWARDS A TRANSDIAGNOSTIC APPROACH IN PAIN 
RELATED INSOMNIA 
While theorists have tried to distinguish between rumination and worry it is clear that the 
two processes are overlapping in that they are repetitive in nature and lead to negative 
outcomes (e.g., rumination leads to depression, worry leads to anxiety). This led some to 
view them as a similar process but applied to different disorder specific content 
(Segerstrom et al., 2000). In order to overcome the domain specific definitions of these 
concepts, Harvey et al. (2004) proposed Recurrent/Repetitive Negative Thinking (RNT) as 
a transdiagnostic process. It encompasses the repetitive nature of rumination and worry 
about concerns from the past, people’s current state and the future. Their reasoning for 
speculating such a transdiagnostic process was the agreement the various definitions of 
rumination and worry shared about the thinking process. Almost all the definitions have a 
repetitive element, that thinking is passive and relatively uncontrollable, and the content of 
the thinking is negative (Ehring & Watkins, 2008).  
Evidence for the transdiagnostic view has come from studies that compared the two 
standardised measures of worry and rumination: the Penn State Worry Questionnaire 
(PSWQ) (Meyer, Miller, Metzger, & Borkovec, 1990) and the Response Styles 
Questionnaire (RSQ) (Nolen-Hoeksema, 1991). In reviewing the studies that have 
compared these two measures, Ehring and Watkins (2008) note that the findings show a 
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high correlation between the measures, that the measures load on common factors in 
structural equation models and that they both lead to anxiety and depression (Fresco, 
Frankel, Mennin, Turk, & Heimberg, 2002; Segerstrom et al., 2000; Siegle, Moore, & 
Thase, 2004). Ehring and Watkins (2008) took these findings to mean that worry and 
rumination share a common process. In additional research, participants had to rate the 
extent to which a range of characteristics related to worry or rumination (Watkins, 2004; 
Watkins, Moulds, & Mackintosh, 2005). The two processes were rated as very similar with 
only the temporal dimension being significantly different: rumination is past focussed, 
worry is focussed on the future. Ehring and Watkins (2008) took this as further evidence 
that worry and rumination share a common process (repetitive thought), but they differ in 
content (e.g., temporal orientation) and supports Harvey and colleagues’ view (2004) that 
repetitive negative thinking is a transdiagnostic process.    
What implication might this approach have for our understanding of insomnia and pain-
related insomnia? Within Harvey’s cognitive model (2002) both rumination and worry are 
seen as “negatively toned cognitive activity”. Hence a scenario might unfold where the 
person with insomnia while focussing on their symptoms of fatigue might attribute them to 
poor sleep the night before (rumination) and thus feel low in mood. The individual might 
then become concerned about their performance at work and whether they will be able to 
sleep that evening (worry). In this scenario only the content of thought varies, whereas the 
repetitive thought process is the same. If this was the case, it would suggest that patients 
with insomnia are engaging in RNT about their sleep disruption and how it will further 
affect them if sleep is disrupted in the future. 
In pain-related insomnia, the “negatively toned cognitive activity” is still taking place in 
the form of RNT (worry and rumination), but its trigger may now include pain and its 
focus includes the causes and consequences of pain. The model may then unfold in a 
similar way to insomnia disorder with patients attributing their fatigue to poor sleep the 
night before caused by their pain (rumination) and thus feeling low in mood. In addition, 
many of the behaviours that lead to the maintenance of insomnia are also apparent in the 
way people typically manage their chronic pain. They may engage in a number of 
behaviours to try and compensate for their poor sleep (staying in bed longer, using 
alcohol), as well as to reduce their pain (as per Eccleston and Crombez’s model (2007)) 
leading to the bedroom becoming associated with a range of behaviours other than sleep. 
They are likely to hold dysfunctional beliefs not just about the impact of poor sleep on 
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their health generally but also on their level of pain (given the evidence that poor sleep 
reduces pain thresholds), leading to further RNT about the quality of their sleeping and 
how to cope with it (worry).  
 
While the above mechanisms for maintaining insomnia and pain-related insomnia seem 
likely given the current evidence, further research is needed to consider exactly how people 
with insomnia and chronic pain view their sleep problem: what do they attribute its cause 
to; what beliefs do they hold with regards to the impact of not sleeping on their pain; are 
they also engaging in safety seeking behaviours related to their pain that have the 
unintended consequence of maintaining their insomnia? All of these questions require 
further empirical investigation but they suggest that cognitive behavioural factors play an 
important role in the maintenance of pain-related insomnia and are thus targets for its 
treatment.  
1.12 TREATING PAIN-RELATED INSOMNIA 
Cognitive behavioural therapeutic approaches target the behavioural and other factors that 
maintain sleep problems (such as dysfunctional beliefs about sleep) either singly or in 
combination in what is now termed cognitive behavioural therapy for insomnia (CBT-I). 
CBT-I combines therapies that have demonstrated efficacy in treating insomnia such as 
behaviour approaches (e.g., stimulus control therapy) (Bootzin, 1973); relaxation training 
(Nicassio & Bootzin, 1974); and cognitive therapy (Harvey, 2005). There is now a large 
and growing evidence base for CBT-I that demonstrates large effect sizes on a range of 
measures such as sleep latency and quality across randomised controlled trials (RCTs) and 
meta-analyses (Edinger & Means, 2005). Only a handful of studies have so far assessed 
CBT-I in patients with chronic pain. 
One of the earliest studies that assessed CBT-I for pain-related insomnia was Morin et al. 
(1989). In a case series using a multiple base-line design with three participants they 
showed that CBT-I that included sleep restriction and stimulus control had a positive 
impact not just on diary measures of sleep quality but also objective polysomnography that 
were maintained at six month follow up. While participants showed improvements in 




In one of the few randomised controlled trials (RCT) of CBT-I in pain-related insomnia, 
Currie and colleagues (Currie, Wilson, Pontefract, & deLaplante, 2000) treated 60 patients 
with chronic pain and insomnia using a group based format. The treatment included 
behavioural elements (stimulus control, sleep restriction) as well as cognitive components 
(challenging negative thoughts about sleep). In comparison to the wait-list control group, 
patients in the CBT-I group had improved sleep onset latencies, sleep quality and 
efficiency both on subjective (sleep diary) and objective (actigraphic) measures that were 
maintained on some of the measures at three month follow-up. The treatment group also 
showed improvements in pain severity rating over time. 
Jungquist et al. (2010) assessed CBT-I in chronic pain after eight weeks of individual 
CBT-I that included: stimulus control, sleep restriction, sleep hygiene and a single session 
focussed on catastrophic thoughts about insomnia. They found that in the CBT-I group, 
sleep latency improved, as did sleep maintenance and efficiency but pain severity did not 
differ between groups. In a trial of CBT-I in patients with fibromyalgia, Edinger, 
Wohlgemuth, Krystal, and Rice (2005) compared patients treated with CBT, sleep hygiene 
or usual care. They found that patients’ sleep diaries showed an almost fifty percent 
reduction in the time spent awake in the patients treated with CBT-I compared to a twenty 
percent reduction in the sleep hygiene group and only a three percent reduction in the usual 
care group. Vitiello, Rybarczyk, Von Korff, and Stepanski (2009) compared CBT-I with an 
attention control group in older patients suffering from osteoarthritis. The CBT-I was a 
group based intervention that included: stimulus control, sleep restriction and hygiene, 
relaxation training and a cognitive component focussing on unrealistic beliefs about sleep 
and loss of sleep. They found that the patients in the CBT-I group, but not the attention 
control group, showed improvements in self reported sleep measures and also pain 
measures that were maintained at one year follow-up. 
While some of the studies show improvements in pain following CBT-I (Currie et al., 
2000; Vitiello et al., 2009) not all of the studies did. Tang et al. (2012b) took this to 
suggest that the reciprocal link between pain and insomnia may not be bi-directional as 
some authors assert. They argue that this is unsurprising given the intractable nature of 
chronic pain. However, in line with cognitive models of chronic pain, using CBT 
approaches that target unhelpful beliefs about pain may lead to improvements in how 
patients live with intractable pain. They piloted a hybrid CBT treatment that included 
elements designed to address insomnia (psychoeducation, stimulus control, sleep 
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restriction, cognitive therapy) with additional components that tackled management of 
chronic pain (goal setting and behavioural activation, pain catastrophising and safety-
seeking behaviour). Data from patients in the CBT group was compared with those 
allocated to a symptom monitoring group. Sleep improved in the CBT group post-
treatment to a greater extent than the symptom monitoring group. While the groups did not 
differ on measures of pain intensity (as predicted), measures of pain interference, fatigue 
and depression all showed greater reductions in the CBT group. Both improvements in 
sleep and pain were maintained at six month follow-up. Interestingly this was the only 
study to address worry as part of the cognitive component of treatment. 
While still in its early stages, the evidence from trails of CBT-I mainly supports its 
effectiveness in patients with chronic pain. However, given that CBT-I is a multi-
component therapy it is not clear which element of the treatment is most effective and/or 
where the greatest clinical change is occurring. Furthermore, only one study so far has 
tackled RNT (in the form of worry) directly in pain-related insomnia. Cognitive models of 
insomnia see worry and rumination as central to its maintenance, suggesting a greater 
emphasis should be placed on factors such as RNT in its treatment. The evidence to date 
suggests this is not currently the case in the CBT-I used for pain-related insomnia, with 
most of the emphasis being on behavioural interventions. Harvey et al. (2004) have 
suggested a number of ways that RNT can be dealt with during treatment for other 
psychological disorders. One approach is to identify and repeatedly trigger worry or 
rumination while helping the patient develop alternative strategies to manage them, such as 
relaxation training or problem solving skills, in a similar way to treatment for generalised 
anxiety disorder (Borkovec & Ruscio, 2001). Use of imagery has also been shown to make 
thinking more concrete and solution-focussed and has been shown to reduce sleep onset 
latencies (Nelson & Harvey, 2003).  
Another way of tackling the content of RNT is to encourage more concrete action-oriented 
thought. While in pain-related insomnia the content of many of these types of thoughts are 
likely to be ‘Why’ type questions, such as, “Why can’t I cope with this pain”, Watkins and 
Baracaia (2002) suggest coaching the patient to use more ‘How’ type questions. In pain-
related insomnia this might be, “How can I manage my pain so I can sleep”. Finally, 
Martin and Tesser (1996) conceptualised repetitive thought as an attempt to find ways to 
achieve personal goals. So if the goals patients set for themselves are unrealistic or conflict 
with other goals this is likely to increase the level of RNT. This seems especially relevant 
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to people with chronic pain who may have the unrealistic goal of cessation of pain 
(Eccleston & Crombez, 2007). Helping patients to identify and move towards more 
functional and realistic goals may help reduce RNT (Harvey et al., 2004). While none of 
the above approaches are new and have formed a part of previous cognitive interventions 
for insomnia (e.g., Espie, 2006) their utility in treating pain-related insomnia has not been 
assessed. The likelihood is, given their effectiveness in insomnia disorder, that these 
approaches will bring benefits to patients with chronic pain and reduce the suffering 
caused by disruption of sleep. Whether this is the case remains an empirical question for 
future research. 
1.13 SUMMARY AND CONCLUSIONS 
Worry and rumination have formed a central part in cognitive theories of insomnia for the 
preceding four decades. But more recently, concerns emerged about whether these were 
the same or two distinct processes. This stemmed in large part from their use within the 
literature as interchangeable constructs and a lack of distinction made in their 
measurement. More recently, researchers began to consider whether these were separate 
processes and played different roles in the maintenance of insomnia. This review sought to 
address this question within the context of insomnia in patients with chronic pain. 
The evidence from the research conducted so far in pain-related insomnia suggests that 
both worry and rumination are important maintaining factors in a similar way to insomnia 
disorder. These processes only appear to differ from insomnia disorder in terms of 
additional content: pain and its consequences. The similarities in the cognitive process (but 
difference in content) across these patient populations add weight to the conceptualisation 
of worry and rumination as forms of repetitive negative thinking (RNT). In both insomnia 
and pain-related insomnia, the RNT can be seen as contributing towards the sleep 
disruption as captured in cognitive models such as Harvey’s (2002). While authors such as 
Carney et al. (2010) have argued for a distinction to be made between rumination and 
worry in insomnia, they acknowledge that the distinction is only in terms of the content of 
the thought process, not the process itself. As a result, worry and rumination do not appear 
to be distinct processes but share a repetitive element that is relatively uncontrollable with 
negative content. The difference between the two appears to be the one of content, with 
rumination focussed on the past and worry on the future. Both these forms of content have 
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been reported in patients with insomnia and chronic pain-related insomnia; with the pain-
related insomnia patients often experiencing further RNT about their pain. In conclusion 
then, it would appear that worry and rumination, as a process of RNT, combine to form a 
‘malignant interaction’ that disrupts sleep, exacerbates pain and maintains distress. As a 
result, therapeutic approaches that disrupt these repetitive thinking processes and replace 
them with more concrete, solution-focussed problem solving approaches would appear to 
be most likely to succeed. By highlighting the role that RNT plays in pain-related 
insomnia, this review suggests a more central role for this process in cognitive therapeutic 
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Background: Early diagnosis of neurodevelopmental conditions such as Autism Spectrum 
Disorders (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) in children are 
enshrined in national UK policy, as is ensuring that parents’/carers’ views shape service 
delivery. Aim: The present study attempted to measure adherence to service guidelines of a 
neurodevelopmental disorders assessment clinic within a Child and Adolescent Mental 
Health Service (CAMHS) to identify service needs. It also assessed parents’/carers’ 
satisfaction with the service and what information should be included in a patient 
information leaflet. Method: An audit of cases referred during 2012 -2013 plus a postal 
survey of parents/carers of children referred during the audit period. Results:  The service 
was mostly compliant with NICE guidelines but quantifying this was difficult under its 
current record keeping. While satisfied with the clinic’s service, the main concern of 
parents/carers was the length of time the assessment process took. Conclusions: Adoption 
of NICE audit tools would help document compliance with guidelines. A patient 







Neurodevelopmental disorders are seen as arising from a child’s atypical brain 
development and result in a range of impairments that impact on communication, 
cognition, behaviour and motor functioning. Within the fifth edition of the Diagnostic and 
Statistic Manual of Mental Disorders (DSM-5) (APA, 2013), Neurodevelopmental 
Disorders include: Intellectual Disability; Communication Disorders; Autism Spectrum 
Disorder (which now encompasses autistic disorder (autism), childhood disintegrative 
disorder, and pervasive developmental disorder not otherwise specified); Attention-
Deficit/Hyperactivity Disorder (ADHD); Specific Learning Disorder (with reference to 
reading, mathematics and written expression); and Motor Disorders (that includes 
Tourette’s  disorder and tic disorders). Similar classifications exist in the International 
Classification of Mental and Behavioural Disorders 10th revision (ICD-10) (WHO, 1992) 
although it still retains the category of Pervasive Development Disorder (PDD) to refer to 
Autism Spectrum Disorder (ASD). In the ICD-10, ADHD is labelled hyperkinetic disorder 
but with more stringent criteria regarding severity of symptoms.  
Clinical diagnoses of neurodevelopmental disorders are based on observations of a child’s 
behaviour (to determine the pattern and severity of impairment) as well as gaining an 
understanding of the child’s developmental history and context that may have a modifying 
influence on the presentation (Moreno-De-Luca et al., 2013). Two of the more difficult 
disorders to diagnose due to the complexity of their presentations are ADHD and ASD. For 
example, ADHD is usually characterised as “maladaptively high levels of impulsivity, 
hyperactivity and inattention” and associated with at least moderate impairment over 
multiple settings (e.g., school and home) and multiple domains (e.g., schoolwork and 
forming relationships with peers) (NICE, 2008, p.15). It requires differentiation from 
conditions that can present with similar symptoms such as conduct disorder and even 
autism spectrum disorder (Weinberg & Emslie, 1991). ASD is diagnosed if impairment is 
observed in “reciprocal social interaction and social communication, combined with 
restricted interests and rigid and repetitive behaviours” (NICE, 2011, p.4). However, 
diagnosis can become more complicated when the child has a high level of functioning and 
shows no delay in language or intellectual development (previously diagnosed as 
Asperger’s Syndrome) (Gillberg, 2002). The National Institute for Health and Clinical 
Excellence (NICE) in the UK has developed guidelines to help Child and Adolescent 
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Mental Health Services (CAMHS) manage and accurately diagnose the presence of ADHD 
and ASD respectively (NICE, 2008, 2011).  
Both guidelines recommend the assessment of children suspected of having these 
conditions should involve gathering information on the child’s behaviour across a number 
of contexts (for example, school and home) and be undertaken by a multi-professional 
team that should include or have access to: Child and Adolescent Psychiatrists, 
Paediatricians, Speech and Language Therapists, Clinical Psychologists, Educational 
Psychologists, and Occupational Therapists. These NICE guidelines include criteria 
against which services can be audited (see Appendix A and Appendix B). While the 
criteria for ADHD cover both diagnosis and clinical management, the ASD criteria only 
cover diagnosis. The ASD guidelines state that children should be seen within three 
months of a referral to the ASD assessment team; there are no specific timescales set out in 
the guidelines for the assessment of ADHD. 
Early recognition and diagnosis are key themes in national UK health policy such as the 
National Service Framework (NSF) for children and young people (Department of Health, 
2004) and Every Child Matters (HM Treasury, 2003). This is especially important in 
ADHD which, if left undiagnosed and untreated, can have a serious impact on an 
individual’s life (ADDIS, 2003; Young, Heptinstall, Sonuga-Barke, Chadwick, & Taylor, 
2005). Early identification of ASD is also seen as vital in helping children develop the 
skills for independent living (as far as possible) as they move towards adulthood (Carr, 
2013; Gillberg, 2002).  
Another important theme in the NSF and Every Child Matters is the involvement of service 
users in shaping health services, with the Healthcare Commission in the UK seeing them as 
vital in informing how services are delivered. Hackett, Shaikh and Theodosiou (2009) 
surveyed through questionnaires, parent and carer perceptions of an ASD assessment 
service within a CAMHS in Manchester, UK. While the majority of parents (95%) were 
satisfied with the service a small number stated dissatisfaction with the length of time the 
assessment process took. One of the recommendations coming out of the survey was the 
development of an information leaflet to be sent to parents and carers before the 
assessment describing the process. The present study used a similar method to Hackett et 
al. to obtain the views of parents and carers of children referred to a clinic that assesses 




The present evaluation sought the views of parents and carers of children who had been 
through the assessment process within a Neurodevelopmental Clinic (NDC) based in a 
CAMHS. In addition, the clinical lead for the NDC also wanted to know from 
parents/carers what information they would like included in a patient information leaflet 
that could help improve the service the NDC provided. Alongside this, the project also 
evaluated the service against the criteria for diagnosis of ASD/ADHD set out in NICE 
guidelines (see Appendix A and Appendix B) as well as addressing specific questions set 
by the clinical lead for the ASD care pathway (see Appendix O). The aim here was to 
assess where the service was meeting NICE criteria but also highlight areas where service 
could be improved in relation to NICE guidance.  
2.4 SERVICE CONTEXT 
The NDC sits within a regional tier 3 community CAMHS for children up to the age of 18 
years. It serves as a specialist assessment clinic for referrals from Swindon (a mainly urban 
area) and Wiltshire (mostly rural) CAMHS respectively. It covers a combined population 
of approximately 600,000 (Swindon 200,000; Wiltshire 400,000) with around 22% being 
under the age of 18 years. The NDC was set up in 2010 following service reorganisation 
that led to a review of the diagnostic pathway in line with national guidelines for ASD and 
ADHD (NICE, 2008, 2011). The main change to the pathway was that a large number of 
first line assessments for ADHD and ASD within the trust would be carried out by 
paediatricians. Prior to this, all assessments were completed by a multi-disciplinary 
pervasive developmental difficulties assessment group (PDDAG). In the new pathway only 
more complex cases that require more detailed multi-disciplinary assessment are seen in 
the NDC. The NDC under evaluation here mainly consists of professionals from 
Psychiatry and Clinical Psychology with further input from the wider multi-disciplinary 
team within community CAMHS.  
All cases referred to the NDC come internally from CAMHS clinicians following a core 
assessment or from the paediatrics complex case pathway. Prior to an initial appointment at 
the clinic, the child or young person’s school is contacted to request information (including 
academic performance, concerns about behaviour, along with strengths and any social 
skills they may have observed) as well as requests to any educational psychologists or 
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speech and language therapists that might have been involved with the child. At the initial 
appointment in the NDC, all parent/carers and children (if appropriate) are asked about 
their concerns and why they think a referral was necessary. They are asked about the child 
or young person’s experience at home and at school and about their medical and 
developmental history (including perinatal details). During these appointments, staff 
observe how the child or young person interacts with them and their parents in terms of 
their social communication, including verbal and non-verbal behaviour. The team then 
spend a brief period separate from the parents to discuss whether a diagnosis can be given 
based on the evidence observed in the room and pre-existing medical records/school 
reports or whether further assessment in the clinic is warranted. Further assessment may 
include the following: naturalistic observation of the child’s behaviour in school; Autism 
Diagnostic Observation Schedule (Lord et al., 1989); Wechsler Intelligence Scale for 
Children – 4th Edition (WISC-IV) (Wechsler, 2004) or similar cognitive assessment 
appropriate to their age and developmental need; Test of Everyday Attention for Children 
(TEA-CH) (Manly, Robertson, Anderson, & Nimmo-Smith, 1999); Conners’ Ratings Scale 
for parents (Conners, 2002a) and teachers (Conners, 2002b). Following further assessment, 
a feedback appointment is made with the parent/carer where the results of the assessment 
are presented with reasons for the team’s conclusions. An opportunity is provided at this 
session to ask questions of the team and seek clarification as well as discuss potential 
treatment options; however the NDC itself does not provide treatment. A written report is 
given to all parents/carers that are routinely shared with their GP. All families will be 





The audit period for the evaluation against NICE guidelines for ASD and ADHD covered 
all referrals to the NDC between 1st April 2012 and 31st March 2013.   
The service has recently moved to the “RiO” electronic patient records system. The system 
is a general electronic record system and is not currently configured to automatically 
capture the type of data suggested by NICE to help in the audit of services. All referrals to 
the NDC were also recorded on a separate Excel spreadsheet by the NDC administrator. 
However, while the administrator did keep a paper record of the assessment process for 
each patient, she expressed concerns about whether it was an accurate reflection of what 
had taken place or was up-to-date. For example, reports can be added to RiO by any 
clinician without the administrator being aware. As a result she was not always able to 
update the paper record. Hence data relevant to the present evaluation had to be extracted 
from within each individual patient record on RiO. This was then entered into a separate 
spreadsheet for analysis. 
For the patient survey, a questionnaire was sent to the parents of every child whose data 
had been included in the evaluation (see Appendix E). The survey sought parents’ views 
about the quality of the service but also what information they would have found helpful 
before attending the clinic. The format for the survey was based on the standard patient 
satisfaction surveys used within the Trust and was provided by the Trust’s Research and 
Development office. This was then adapted in consultation with the clinical lead for ASD 
to ask patients about issues relevant to the NDC. The survey collected: basic demographic 
data; views about the length of time waiting for an appointment; parents’ views about the 
assessment process; their opinion about the diagnosis; the feedback appointment and 
report. The survey also asked whether they thought an information leaflet would have been 
helpful and what information they thought it should contain. The survey included a 
stamped address envelope to return to the CAMHS admin team. Two weeks after sending 
the surveys, a reminder letter was sent (with a further copy of the survey) to invite parents 
to respond if they had not already done so. Approval for the evaluation and survey was 





Between April 2012 and March 2013 there were 62 referrals to the NDC. Of these 42 were 
male and 20 female. Forty four of the referrals came from Swindon with 18 coming from 
Wiltshire. The age ranges of the children referred to the clinic during the audit period are 
shown in Table 2.1. The majority were between the ages of 11-15 years old. The number 
of referrals from each of the different professions referring children into the NDC is shown 
in Figure 2.1.   
Table 2.1: Age ranges of the children referred to the NDC over the audit period. 
Age range: No. of children referred 
Under 5 1 
5-7 yr old 7 
8-10 yr old 5 
11-15yr old 36 




Figure 2.1: Number of referrals to the NDC over the audit period according to the 
profession of the referrer 
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The largest number of referrals to the clinic came from Psychiatrists (17, 27%) closely 
followed by Psychologists (14, 23%). There was only one referral during the period from a 
Consultant Paediatrician. However, this most likely reflects the fact than many of those 
referred through the paediatrics complex case pathway will have initially been seen by a 
CAMHS professional before that professional then refers them to the NDC. 
2.6.1 TIMESCALE OF THE ASSESSMENT PROCESS 
The median time to first appointment was 2.02 months with an inter-quartile range of 1 
month.  As shown in Figure 2.2, 86% of children were seen within 3 months of being 
referred.   
 
 
Figure 2.2: Cumulative percentage of referrals against time to first appointment (months) 
 
In total 8 children were not seen within 3 months of referral. All of these children were 
referred for an assessment of ASD. The reason they were not seen within the 3 month 
timescale was due to either the initial appointment at the clinic not being kept by the 
parent/carer, or unavoidable rescheduling of appointments beyond the control of the clinic. 
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The parents/carers of 3 (4.8%) children referred to the clinic decided to withdraw from the 
assessment process. At the time of the audit, 13 (21%) children had not completed the 
assessment. 
2.6.2 ASSESSMENT & DIAGNOSIS 
All of the children in the clinic were assessed by two or more professionals from the multi-
disciplinary team. Sixteen children underwent cognitive assessment as part of their 
assessment process; 8 using the WISC-IV and 8 using the WISC-IV plus the TEA-CH. 
Nineteen children (30.6%) were observed by a member of the team while at school at the 
time of the audit, with one child still awaiting an observation. Thirty children (48.4%) were 
assessed using the ADOS, all of whom were referred for ASD or ASD/ADHD assessment. 
2.6.3 ADHD 
Seven children were referred for an assessment of ADHD. One of the children was still 
awaiting an initial assessment at the time of the audit. All of the remaining 6 children were 
assessed using the Conners’ Ratings Scale by both parents and school teachers. Three of 
the children were also observed by one of the NDC team while at school. Three of the 
children underwent cognitive assessment that comprised both the WISC-IV and the TEA-
CH. All 6 children’s parents were interviewed by the NDC team about their child’s 
developmental history.  
Three of the seven children referred for ADHD were still awaiting a diagnosis at the time 
of the audit. Of the four that were diagnosed, one was diagnosed with an attachment 
disorder and another was diagnosed with a learning disability. The remaining 2 children 
were diagnosed with ADHD and were prescribed Aripiprazole and Concerta respectively 
under the care of a Consultant Psychiatrist in CAMHS. One of the families of those with 
the ADHD diagnosis was offered a parenting intervention. The other, being over 15 years 
old, received individual psychological therapy within CAMHS.  These two children were 
referred to the clinic by a Social Worker and Consultant Psychiatrist respectively (the 






Table 2.2: Profession of referrers to the NDC for an ADHD assessment. 
Profession of referrer: Frequency Percent 
 
Clinical Psychologist 1 14.3 
Consultant Psychiatrist 2 28.6 
Family Therapist 2 28.6 
Social Worker 2 28.6 
Total 7 100.0 
2.6.4 ASD/ADHD 
Seven children were referred for an assessment of ASD and ADHD by the referring 
clinicians. One of these did not continue with the assessment process. All of these children 
were assessed using the Conners’ Ratings Scale but only three of these received ratings 
back from the parents. Four of these children were observed by an NDC team member 
while at school.  Five of the children completed cognitive assessments; 3 using both the 
WISC-IV and the TEA-CH; one WISC-IV only and one the TEA-CH only. All six 
children’s parents were asked about the child’s developmental history. 
Of the 6 children that completed the assessment process, none received a diagnosis of 
ASD. Only one child received a diagnosis of ADHD and was offered a parenting 
intervention and placed on Concerta medication under the care of a Consultant Psychiatrist 
in CAMHS. This child was referred to the NDC by a Consultant Psychiatrist. The 
profession of the referrers to the NDC for an assessment of ASD/ADHD are shown in 
Table 2.3. The remaining 5 children received the following diagnosis respectively: 
Anxiety/Low Self-esteem; Anxiety/OCD; Emotional/behavioural problems; Generalised 






Table 2.3: Profession of referrers to the NDC for an ASD/ ADHD assessment 
Profession of referrer: Frequency Percent 
 
Clinical Nurse Specialist 2 28.6 
Clinical Psychologist 1 14.3 
Consultant Psychiatrist 1 14.3 
Social Worker 3 42.9 
Total 7 100.0 
2.6.5 ASD 
Forty-eight children were referred to the NDC for an assessment of ASD. Of these, 2 
dropped out of the assessment process and did not continue and a further 10 had not 
completed the assessment at the time of audit. Three of the children referred were assessed 
using the Conners’ Ratings Scale completed by their school. Twelve (25%) of the 
children’s behaviour was observed while at school by a member of the NDC team. Eight 
children (18.6%) underwent a cognitive assessment; seven (16.3%) by the WISC-IV with 1 
child assessed by WISC-IV and TEA-CH. At the time of the audit, one child is still 
awaiting an assessment of their developmental history. Table 2.4 shows the profession of 









Table 2.4: Profession of referrers to the NDC for ASD assessment 
Profession of referrer: Frequency Percent 
 
Clinical Nurse Specialist 4 8.3 
Clinical Psychologist 12 25.0 
Consultant Paediatrician 1 2.1 
Consultant Psychiatrist 14 29.2 
Family Therapist 5 10.4 
Psychotherapist 5 10.4 
Senior Mental Health Practitioner 4 8.3 
Social Worker 3 6.3 
Total 48 100.0 
 
Figure 2.3 shows the outcomes for the 36 children who were referred for ASD to the clinic 
and completed the assessment process. Sixteen children (44.4%) received a diagnosis of 
ASD (4 (11.1%) for ASD and 12 (33.3%) for Asperger’s Syndrome).  Of those who did 
not receive a diagnosis of ASD, the largest percentage had an attachment disorder (19.4%) 
disorder. Four children (11.1%) had an existing diagnosis of ADHD and there was no 





Figure 2.3:  Outcomes of patients referred to the NDC for an assessment of ASD.  
ASD=Autism Spectrum Disorder; ASD (AS) =Asperger’s Syndrome; 
OCD=Obsessive Compulsive Disorder; ED=Eating Disorder; LD=Learning 
Disability 
 
2.6.6 TIME TO COMPLETE ASSESSMENT 
Sixteen (25%) children attending the NDC were able to be given a diagnosis at their initial 
appointment. The median number of appointments (including their initial appointment) in 
the clinic was 3 with only one child having 6 appointments.  The mean time from the initial 
appointment to being given an outcome from the clinic was 3.8 months with the range 
extending as far as 12 months.   The inter-quartile range was 0 – 6 months. The cumulative 





Figure 2.4:  Cumulative percentage of referrals against time from initial appointment to 
feedback appointment in months 
2.6.7 INTERVENTIONS 
For the 46 children who had completed the assessment process in the clinic, their 
destination following assessment is presented in Figure 2.5. The two main destinations for 
children following a diagnosis in the clinic are either a psychiatric (30.4%) or 
psychological (19.6%) intervention within CAMHS. A number of children (10.9%) did not 





Figure 2.5: Destination of referrals following completion of assessment in NDC 
2.6.8 SATISFACTION SURVEY 
The complete data set for responses to the survey are presented in Appendix F. A total of 
14 surveys were returned (22.6% of the total). The majority of those responding (57%) had 
children who were between 11 and 15 years old. The male to female ratio of 2:1 in overall 
referrals to the clinic over the audit period is roughly matched in the respondents to the 
satisfaction survey. Eight respondents claimed to have waited over 6 months for an 
appointment in the clinic with one respondent stating they had to wait over 18 months. 
Only 5 respondents agreed or strongly agreed that the waiting time was reasonable. 
2.6.8.1 The assessment process 
All the respondents thought that staff explained fully why their child was being assessed in 
the clinic, except one who stated they did not know/remember. Only three of the 
respondents thought that the assessment process did not address their child’s difficulties. 
The majority of respondents felt encouraged to participate in the assessment process and 
that their views were actively sought by staff, however two felt this was not the case. Of 
these two, one parent thought that the outcome of the assessment had already been decided 
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by staff before their child was even seen. The other did not feel that staff listened to their 
views and acted as though they were the experts on their children.  
2.6.8.2 The outcome of the assessment 
All of the respondents who answered had received a diagnosis of their child’s condition 
that was fed back to them from a member of the team.  Eight of the 14 respondents 
received a diagnosis of ASD for their child while 2 received a diagnosis of ADHD. The 
remainder received either no formal diagnosis or did not respond. Overwhelmingly 
respondents agreed with the diagnosis. However two did not agree with one of these being 
one of the respondents who had not felt listened to by staff. All of those who responded felt 
they had been given the opportunity to discuss their feelings about the diagnosis but two 
felt that the diagnosis had not been explained properly to them. One of these respondents 
stated they were unsure what the diagnosis meant in terms of getting help for their child. 
The other also felt that staff had not listened to them and did not agree with the diagnosis 
and did not think the report from the clinic was useful. 
Three of the respondents did not feel they were given information about useful resources 
but one of these stated this was because their child had not been given a diagnosis. While 
six respondents stated they had been given information about useful voluntary and social 
support networks, seven respondents stated they had accessed them. Of those that 
responded, most had accessed the National Autistic Society. 
2.6.8.3 Satisfaction with the assessment process 
Eight of the respondents thought that the service they received from the clinic was either 
“Good”, “Very Good” or “Excellent”. Only two rated the service as not satisfactory and 
both of these were parents who felt they had not been listened to by staff and that the 
assessment process had not addressed their child’s difficulties. 
While five respondents thought that an information leaflet would have been helpful before 
attending the clinic, five felt it would not have helped but none stated why. Of those that 
felt it would have been helpful, five wanted to know what was going to happen at the clinic 
while three respondents wanted to know more about why they were attending the clinic, 
how long the assessment process would take and who they would be seeing at the clinic. 
Two respondents wanted information on what the different outcomes of the assessment 






Respondents were given the opportunity to provide written responses at the end of the 
survey on aspects of the assessment process that they found helpful, unhelpful and what 
could be improved. 
Two respondents stated that the staff at the clinic had been friendly and approachable with 
their views about the process being taken seriously. Two also stated that the information 
provided to them was clear, jargon free and explained to them by the members of the clinic 
team and one stated they felt unhurried by the team and given enough time to process the 
information. Three respondents also mentioned the professional and positive manner of the 
staff. One respondent felt that appointments were made promptly and that their child’s 
needs had been addressed. 
While it has already been stated that two respondents did not feel their views were listened 
to, the other responses regarding what was not helpful revolved around waiting times for, 
and cancellation of, appointments. One respondent stated that appointments had been 
cancelled at short notice and that there had been a delay in providing feedback from the 
assessment process. This made them feel let down and demoralised. Another also stated 
that the long delay for an initial appointment was unhelpful, as was having to attend the 
clinic a number of times before a diagnosis could be given.  
When asked about what could be improved, one suggested a written list of the conditions 
that the clinic assesses for. Another suggested speeding up the assessment process from the 
initial appointment to the final feedback session. Finally, one respondent felt that 
information about the statementing process in schools would have been helpful as well as 




2.7 DISCUSSION & IMPLICATIONS 
2.7.1 AUDIT 
The guidelines set out by NICE recommend that children referred for an assessment of 
ASD should be seen within 3 months (Criteria 1, see Appendix A). All patients referred to 
the clinic are given an initial appointment within three months of the date of the referral 
and the majority of patients (86%) were seen within that timeframe. Given that the reasons 
for the 8 patients who were not seen within three months were largely beyond the control 
of the clinic it is difficult to see what improvements could be made to make the clinic 
100% compliant with this criterion.   
The NICE Criterion 2 for what should be included in an ASD assessment is routinely 
covered during the initial appointment or from further assessment as required.  All 
parents/carers are provided with a written report at the end of the assessment that is shared 
with their GP (Criteria 4 & 5) and offered a follow-up appointment within six weeks of the 
end of the assessment in the NDC. Only Criterion 3, a physical examination, is not 
conducted by the NDC. If the child or young person was referred through the paediatrics 
complex case pathway they would have been given a physical examination at that point. 
Alternatively if this was not the case and was required then the NDC would refer to 
paediatrics and ask them to contribute to the assessment. 
In the NICE Guidelines for ADHD, only Criteria 1 and 2 relate to assessment (see 
Appendix B). When a child or young person is referred to the clinic for suspected ADHD, 
the same structure for assessment as above is followed but the emphasis is more on the 
diagnostic criteria in DSM-IV/5 and ICD-10 for ADHD. All of the children referred to the 
clinic during the audit period suspected of having ADHD were assessed in the school 
environment either via their school teachers using the Conners’ Ratings Scale, by written 
reports from the school, or by direct observation in school by a member of the NDC team. 
Information from the school, combined with parents/carers reports about behaviour in the 
home environment, allows assessment across multiple settings. This ensures the NDC was 
compliant with Criteria 1 and 2 of the ADHD NICE Guidelines.  
Criteria 3 – 7 of the NICE Guidelines relate to treatment options once a diagnosis of 
ADHD has been made. Only 3 patients were diagnosed with ADHD during the audit 
period. All of these patients were subsequently offered medication for the condition and 
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two were offered a parenting-training programme. Criteria 8-10 refer to young people 
about to transition to adult services at the time of assessment; there were no patients in that 
position during the audit period.  All patients and their parents/carers are provided a 
written report about their diagnosis but they are not routinely provided with standardised 
written information such as the “Understanding NICE guidance” booklet as per Criteria 11 
and 12. 
In general, the NDC meets the majority of the Criteria set out in the NICE Guidelines but 
many of these are difficult to quantify due to the nature of the electronic records system 
adopted by the Trust within which the NDC sits. For those that could be quantified, having 
to access individual records and reports to obtain the data on each patient’s assessment was 
time and labour intensive. NICE have developed audit support tools for both of these 
conditions (see Appendix C and Appendix D) that allow recording of activity against the 
criteria. The tool is a relatively straightforward tick-box record that could be maintained in 
either paper or electronic form. These would allow a more rapid audit of the service in 
future and help provide documentation to show the NDC meets NICE guidelines.   
2.7.2 SATISFACTION SURVEY 
In general, the majority of parents/carers who responded to the survey felt the service they 
received in the clinic was a good one. Respondents commented that staff were friendly, 
professional, listened to their concerns and explained the outcome of the assessment, 
giving them enough time to process and understand the diagnosis.  
The main concern of those parents/carers who responded to the satisfaction survey was the 
length of time the assessment process took. It is interesting to note that 9 respondents 
stated that they had to wait over six months for an appointment at the NDC. From the audit 
data, only one patient had to wait over six months to be seen. The mis-match in findings 
may be due to a number of reasons. A simple explanation is that parents/carers perceive the 
time taken to be seen in the clinic as much longer than it actually is. However a more 
reasonable explanation is that for the parents/carers, the process of finding out what is 
causing their child’s difficulties starts much earlier than the time at which the referral 
occurs. Hence the time it takes them to find answers is much longer than is perhaps being 
recognised by health professionals.  This was exacerbated for some respondents by the 
number of appointments they had to attend and the time taken to get a feedback 
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appointment. It is difficult to see how, when a patient requires a comprehensive 
assessment, the number of appointments can be reduced. Assessments such as the ADOS 
and WISC-IV are time intensive and cannot be combined into a single appointment. 
Furthermore, constraints on staff time also make it difficult to complete the assessment 
within a shorter timeframe. The concerns of respondents here about the length of the 
assessment process is a similar finding to Hackett et al. (2009) who recommended 
providing an information leaflet for parents/carers that should be sent with the initial 
appointment letter. This leaflet might explain the assessment process and timescales 
involved as a way of managing parents’/carers’ expectations. 
In the current survey, parents/carers were asked directly whether an information leaflet 
would have been useful. Only half of those that responded felt it would have helped, but of 
those that did the majority wanted information about what was going to happen at the 
clinic when they attended. Other concerns were how long the assessment process would 
take and more information about why they were attending a specialist clinic. Two 
respondents wanted information on the potential outcomes of the assessment and what 
happens after the process is completed.  
The satisfaction survey reported in Hackett el al. (2009) was much more comprehensive 
than the one reported here and asked questions about the pre-attendance period as well as 
after the assessment process. Given the concerns raised by respondents about the length of 
time the assessment process takes, a more detailed exploration of how these could be 
mitigated for parents/carers given the constraints of the service is warranted. The survey 
reported here was made intentionally brief over concerns that parents/carers would not 
respond if it was too long. Given that only 22% did respond the choice seems vindicated. 
In future, if a more detailed survey is sent to parents/carers one option might be to follow 
up the initial mail survey with a telephone call. This was the strategy adopted by Hackett et 





Based on the above discussion, the following recommendations are suggested: 
 Implement the NICE audit tools for ASD and ADHD (Appendix C and Appendix 
D) as part of the record keeping within the clinic. This would simplify the analysis 
process and produce an audit trail to demonstrate the NDC is compliant with NICE 
guidelines. 
 Develop an information leaflet to be sent to parent/carers with the initial 
appointment letter. The leaflet should describe the assessment process and what 
will happen when attending the clinic as well as managing expectations about the 
potential length of the assessment process. 
 Development of a satisfaction survey that could routinely be provided to 
parents/carers to ensure that their views help to shape service delivery as per 
national policy (e.g. NSF and Every Child Matters). 
 For clinicians and service managers to be aware that parents/carers are likely to 
perceive the assessment process as longer than services see them (due to having 
likely seen a number of health care professionals prior to referral to the NDC).  
While the NDC is meeting NICE guidelines, parents/carers perceive the time to be 
seen by a specialist as much longer that the current 3 month maximum. 
2.9 FEEDBACK AND DISSEMINATION  
The commissioner of the project was the Trust’s lead for ASD. A written copy of the 
report was sent and read by her and another clinical psychologist working in CAMHS. 
Both felt that the report was very positive about the service and would be helpful within 
the Trust to guide service thinking and planning. At the suggestion of the clinical lead, it 
was agreed that I would present the findings of the report to a review meeting of the NDC 
in June 2014. Attending the meeting will be the Consultant Psychiatrists and Psychologists 
from the NDC as well as service managers, clinical governance managers and 
representatives from divisional management and audit. The commissioner felt this would 
underline the usefulness of the work and keep the issues it raises on the wider agenda 
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Multiple Sclerosis (MS) is an incurable disease which is commonly associated with 
psychological complications. Previous research by Hayter and colleagues found that in 
patients with MS, health anxiety (HA) can account for part the variance in quality of life 
(QoL) independent of any physical and cognitive impairment caused by the disease and 
that MS patients with health anxiety perceived their (intact) physical and cognitive 
performance as impaired relative to MS patients without health anxiety, attributing the 
impairment to MS. The findings suggest that such misperceptions might be useful targets in 
the treatment of health anxiety in MS using adapted cognitive behavioural therapy (CBT). 
The first of two studies presented here sought to replicate the findings from Hayter et al. 
before a second presents the findings from a brief case series of treatment for HA using 
CBT. In Study 1, twenty participants with Relapsing and Remitting MS were screened for 
HA and assigned to either a high or low HA group. Participants then completed 
assessment of cognitive and physical functioning before rating their performance on these 
tasks. Measures of QoL, mood and physical disability were then completed. Four 
participants in the high HA group subsequently received six sessions of CBT using a 
consecutive AB case series in Study 2. Study 1 replicated the main findings from the earlier 
study. In Study 2, three of the four patients who received treatment showed substantial 
improvements in HA and mood and all showed improvement in QoL. Given the high rates 
of HA in MS patients and its impact on QoL, this case series suggests a brief CBT 
intervention could significantly improve patients’ wellbeing. The findings pave the way for 
larger, controlled studies into the effectiveness of CBT for health anxiety in MS.      
Keywords: Cognitive behavioural therapy; psychological therapy; Multiple Sclerosis; 




Relapsing and remitting multiple sclerosis (RRMS) is the most common form of MS 
affecting around 80% of MS patients. Following an initial attack that can impact both 
physical (e.g., fatigue, numbness, pain, blurred vision) and cognitive functioning (e.g., 
slowed processing speed, attentional problems) through demylination of brain nerve fibres, 
patients can recover functioning for an unpredictable period before further attacks cause 
progressive deterioration. Given the unpredictable and fluctuating nature of RRMS it is 
unsurprising that many patients worry about when further attacks may occur, with rates of 
anxiety, in particular health anxiety (HA), high in this patient group (Chwastiak et al., 
2002; Kehler & Hadjistavropoulos, 2009; Korostil & Feinstein, 2007). Although earlier 
work has focussed on general anxiety and depression, more recent work suggests HA may 
be particularly relevant to the problems experienced by MS patients. Previous research 
found that RRMS patients with health anxiety had lower quality of life (QoL) compared to 
patients without health anxiety independent of physical disability (Hayter, Salkovskis, 
Morris, & Silber, in process). They also found that the health anxious RRMS patients 
misappraised their performance on physical and cognitive tasks and suggested that these 
might be targets for treatment using cognitive behavioural therapy (CBT) to reduce health 
anxiety, and potentially improve QoL. The studies presented here first sought to replicate 
the earlier study but then went on to treat the health anxious RRMS patients using a brief 
CBT intervention; presenting the findings from a consecutive AB treatment case series.  
Identifying ways of helping people with poor QoL and distress around MS is important 
because MS itself is, a) incurable and, b) common. Approximately 110 people per 100,000 
in the UK suffer from MS (Richards, Simpson, Beard, & Tappenden, 2002). Around 85% 
of people with MS experience physical impairments that make the activities of daily living 
(such as cooking, cleaning, work and socialising) difficult (Bakshi, 2003). Cognitive 
difficulties, such as problems with short term and working memory, executive functioning, 
visuospatial abilities and reduced processing speed, affect around 65% of patients (Amato, 
Ponziani, Siracusa, & Sorbi, 2001; Bobholz & Rao, 2003; Rao, Leo, Bernardin, & 
Unverzagt, 1991a) and can disrupt employment and social relationships (Rao et al., 
1991b). 
While it unsurprising that high rates of anxiety and depression exist in patients with 
RRMS, studies have found that emotional factors are more predictive of patients’ 
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subjectively rated QoL than physical or cognitive impairment (Benedict et al., 2005; 
Dennison, Moss-Morris, & Chalder, 2009; Janssens et al., 2003). For example, Benedict et 
al. (2005) found that cognitive dysfunction accounted for none of the variance in a measure 
of health related QoL but instead was predicted by both depression and fatigue. Janssens et 
al. (2003) found in their study that the extent to which physical disability affects QoL in 
MS patients was moderated by anxiety and depression. 
Cognitive accounts of anxiety and depression state that a person’s symptoms are 
maintained through processes linked to unduly negative appraisals. Of particular relevance 
here is the cognitive model of health anxiety (Salkovskis & Warwick, 1986; Warwick & 
Salkovskis, 1990). When a person experiences ambiguous physical or cognitive symptoms 
(often due to “normal” bodily variations), their prior beliefs about illness lead to 
misinterpretation of these symptoms as signs of severe threat (i.e., a severe illness). In the 
model, the person remains focussed on threat relevant information through attentional, 
physiological and behavioural processes that lead to further misinterpretation and potential 
increases in anxiety. The model has recently begun to be applied to patients in physical 
health settings (e.g., The CHAMP trial, (Tyrer et al., 2011b)). As such, it is particularly 
relevant to RRMS as high levels of anxiety can lead to transient physiological symptoms 
that mirror that of the illness (e.g., pins and needles, dizziness, pains etc.). Hence RRMS 
patients vulnerable to health anxiety may experience these normal bodily variations but 
misappraise them as signs of MS relapse, leading to increased anxiety and thus further 
anxiety symptoms. This would suggest that the rates of health anxiety in RRMS are likely 
to be high and indeed Kehler and Hadjistavropoulos (2009) found the rate to be 
approximately 25% while Hayter et al. (ibid) found 29%.   
Misappraisal in terms of exaggerated threat has been found in studies with MS patients 
who focus excessively on bodily sensations (Vercoulen et al., 1996) and attribute them to 
MS (Skerrett & Moss-Morris, 2006) with associated increases in fatigue and poor social 
adjustment. Catastrophising about bodily sensations has also been found to predict reduced 
psychological functioning even after MS related factors have been controlled for (Osborne, 
Jensen, Ehde, Hanley, & Kraft, 2007). MS patients who are anxious or depressed are also 
more likely than those not anxious or depressed to misperceive themselves as more 
cognitively impaired than they actually are based on objective neuropsychological test 
performance (Benedict et al., 2004; Julian, Merluzzi, & Mohr, 2007; Lovera et al., 2006; 
Maor, Olmer, & Mozes, 2001; Middleton, Denney, Lynch, & Parmenter, 2006).  
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In a recent study, Hayter et al. (in process) found that health anxious patients also had 
lower QoL compared to non health anxious RRMS patients, even after their level of 
physical disability was controlled for. The health anxious patients were also more likely 
than non health anxious patients and healthy controls to attribute their ambiguous bodily 
sensations to their MS. Hayter et al. asked their participants to complete short “objective” 
assessments of their cognitive and physical functioning as well as rate their perceived 
performance on these tasks. Even though there was no difference in performance, the 
health anxious MS patients subjectively rated their performance as worse than the non 
health anxious and control groups and were more likely to attribute their poor performance 
to their MS. These findings suggest health anxiety in patients with RRMS is leading them 
to perceive themselves as more physically and cognitively impaired than they really are: 
with a concomitant reduction in QoL.  
The implication of the above findings is that potentially QoL in health anxious RRMS 
patients could be improved through treatment focussed on HA. Randomised controlled 
trials (RCTs) have shown CBT to be effective in treating health anxiety in psychiatric 
populations (Clark et al., 1998; Greeven et al., 2007; Seivewright et al., 2008). The 
approach is to help patients actively explore (through discussion and behavioural 
experiments) the validity of an alternative understanding of their problem as one of 
misinterpretation of bodily sensations that lead to safety seeking behaviours, 
hypervigilance, physiological arousal etc., that in turn maintain their symptoms – rather 
than one of having a serious illness. More recently the approach has been applied in a 
physical health setting in the CHAMP trial (Tyrer et al., 2013). This was a multi-centre 
RCT where patients with health anxiety across a range of co-morbid physical health 
conditions received on average six sessions of a manualised CBT intervention for health 
anxiety delivered by non CBT specialist health care professionals in secondary care 
settings. Twice as many patients in the CBT group achieved normal levels of health 
anxiety compared to those in the control group with no significant increase in total 
treatment cost. This led the authors to suggest that a brief CBT intervention was cost 
effective in treating health anxiety in patients with physical health conditions. 
Relatively few studies have explored the effectiveness of CBT in treating co-morbid 
psychological problems in MS patients. A recent Cochrane review of psychological 
interventions in MS (Thomas, Thomas, Hillier, Galvin, & Baker, 2006) found that generic 
CBT lead to significant improvements in depression symptoms in two studies that 
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compared it to treatment as usual (Larcombe & Wilson, 1984; Mohr et al., 2000) but found 
no difference when compared to antidepressant medication (Mohr, Boudewyn, Goodkin, 
Bostrom, & Epstein, 2001). Askey-Jones, David, Silber, Shaw, and Chalder (2013) state 
that to date, no studies have considered the effectiveness of CBT in treating anxiety 
disorders in MS.   
The misperception by MS patients of physical and cognitive functioning found in the 
Hayter et al. (ibid) study suggest this could be a useful target in treatment. For example, 
Tang and Harvey (2006) targeted misappraisals in a subgroup of insomnia patients 
whereby they perceived themselves as having sleep problems when in fact they displayed 
normal patterns of sleep. The authors developed a behavioural experiment where patients 
compared their self-rated sleep pattern against objective feedback from actigraphy, leading 
to improvements in patients’ subsequent sleep ratings. Similarly, using objective data from 
their performance on physical and cognitive tasks might help MS patients with health 
anxiety reappraise their level of functioning and reduce levels of health anxiety. Hence a 
brief adapted CBT intervention for health anxiety (CBT-HA) may be beneficial to patients 
with RRMS suffering from health anxiety.  
In the second study presented here, the findings of an exploratory investigation into the 
effectiveness of a brief six session CBT-HA intervention in RRMS patients are presented 
through a series of case studies. Six sessions was chosen as this was the average number of 
sessions needed in the CHAMP trial (Tyrer et al., 2013) to demonstrate significant 
improvements in health anxiety and is generally classed as a brief psychological 
intervention. However, before doing so, the Hayter et al. (in process) study was replicated 
to see if the findings are reproduced across different samples (a large proportion of Hayter 
et al.’s participants had university degrees (>60%) which is not representative of the UK 
population as a whole). In Study 1, ratings of QoL, self-rated performance on a physical 
and cognitive task and extent to which performance on these tasks is attributed to MS, 
were compared across participants with low and high levels of health anxiety. If the Hayter 
et al. findings generalise, then RRMS patients with health anxiety would rate their QoL 
and task performance as lower than RRMS patients without health anxiety, and attribute to 
a greater extent their performance on these tasks to MS. Replicating Hayter et al.’s findings 
also provides a clinical justification for treating participants using a cognitive model of 
health anxiety with a specific focus on misappraisals of cognitive and physical functioning 
and allowed the identification of targets for treatment (via behavioural experiments) during 
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therapy. As Hayter et al. demonstrated that health anxiety affects QoL independent of 
physical disability, it was expected that in Study 2 health anxious participants who went on 
to receive a brief CBT-HA intervention would not only show reductions in health anxiety 
but also improvements in QoL.  
3.3 METHOD 
3.3.1 DESIGN 
Study 1 sought to replicate the Hayter et al. study using an independent groups design with 
level of health anxiety (high health anxiety (HiHA) or low health anxiety (LoHA)) as a 
between-subject factor. Participants from Study 1 with a score of 18 or above on the Short 
Health Anxiety Inventory (SHAI) were invited to take part in Study 2 where they were 
offered six sessions of CBT-HA. The original plan was to use the same cut-off scores from 
the SHAI that were used by Hayter et al. to assign participants to either the HiHA group 
(>18) or LowHA group (<10). However to difficulty locating participants that met the 
inclusion criteria meant this plan had to be abandoned, as it would have meant an even 
smaller sample size, and instead a median-split on the SHAI was used to assign 
participants to groups. 
Study 2 evaluated the effectiveness of a brief form of CBT-HA using a consecutive single 
case series A–B design (Barlow & Hersen, 1984) with follow-up. For this design, all 
patients were assigned to no-treatment baselines of 2 weeks. Individual baselines acted as 
control periods. The original plan was to control for non-specific therapy effects by 
counter-balancing CBT-HA with 6 sessions of Relaxation Training but time limitations 
meant this was not possible. CBT-HA was delivered by the study’s lead author (NC) who 
has received doctoral level training in clinical psychology and accredited Level 2 training 
in CBT (British Association for Behavioural and Cognitive Psychotherapies; BABCP). 
One of the study authors (PS) was responsible for developing the cognitive model of health 
anxiety and is a recognised world authority in the field. During the delivery of treatment, 
NC was supervised by PS through fortnightly sessions using audio recordings from 
treatment to ensure adherence to the cognitive model of treatment. Follow up of patients 




Participants were recruited from the caseloads of the Community Neuro & Stroke Service 
and MS Neurology nurse specialists in Bath, UK. All participants recruited from these 
caseloads had a definitive diagnosis of RRMS. Participants were contacted initially via 
telephone and asked if they would like to take part. The aims of the study were explained 
to potential participants and what they would be asked to do in the study (i.e., complete the 
study measures, cognitive test and handgrip measure). It was explained that their 
participation was completely voluntary and independent of any care they were currently 
being provided. If they initially agreed, an appointment was made for the researcher (NC) 
to visit the participants at their home where the study aims were explained to them again 
and they were given the Participant Information Sheet for Study 1 (see Appendix L) and  
asked to provide written consent to take part in the study(see Appendix M). Only three of 
the patients identified from the caseloads declined to take part in the study saying they 
were too busy with work commitments. Problems with recruitment meant that five 
participants were also recruited from a local MS National Therapy Centre. In total, 20 
participants took part in Study 1 (17 female, 3 male). This is lower than the original plan of 
24 participants (12 in each group) due to already stated problems identifying relevant 
participants from the various clinicians’ caseloads. However, the number recruited to the 
study is still above that required from the power analysis (n=16) and was done to allow for 
the testing of the study hypotheses via parametric data analysis.  All participants were over 
the age of 18 years (range 21 – 54 years), were white Caucasian, and gave written 
informed consent to take part in the study. Ethical approval for the study was obtained 
from the Oxford C NHS Research Ethics Committee (ref: 13/SC/0547) and the University 
of Bath’s Department of Psychology Ethics Committee. 
Six participants who scored above 18 on the Short Health Anxiety Inventory (SHAI) were 
invited to take part in Study 2. It was explained that their scores on the SHAI were high 
and asked if they were feeling anxious about their health. It was explained that a second 
phase of the research was assessing a psychological therapy for health anxiety and they 
were asked if they would like to participate in this research. Participants were asked to look 
through with the researcher the Participant Information Sheet for Study 2 (see Appendix P) 
where a brief overview of CBT was given, stating that they would be offered up to 6 
weekly session of CBT. If they agreed to take part they were again asked to give written 
informed consent to take part in the Study 2. Two of the six participants who were eligible 
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to take part in Study 2 declined without giving reasons, leaving four women with age 
ranges from 22 to 43 years to take part. The details of cases and their treatment are given 
below in the Results section.   
3.3.3 MEASURES 
Health anxiety (see Appendix Q): Health anxiety in participants was assessed with a 
modified version of the 14 item Short Health Anxiety Inventory (SHAI). The 14 items 
assess basic health-anxiety symptoms. Scores above 18 are seen as indicating clinical 
levels of health anxiety (Seivewright et al., 2004) and would meet DSM diagnostic criteria 
for hypochondriasis (APA, 2013; Salkovskis, Rimes, Warwick, & Clark, 2002b) while 
scores above 15 suggest the person is suffering symptoms of health anxiety. The SHAI is a 
reliable and valid measure in the general population (Salkovskis, Rimes, Warwick, & 
Clark, 2002a) and has been modified for use with patients with MS (Kehler & 
Hadjistavropoulos, 2009). Continuous monitoring of health anxiety in participants 
undergoing treatment in Study 2 was assessed using a modified version of the 6 item 
Health Anxiety Inventory, the Very Short Health Anxiety Inventory (VSHAI). The VSHAI 
has not been formally validated but in previous studies was found to correlate highly 
(r=0.8) with the SHAI (Salkovskis, personal communication).  
Mood (see Appendix R): Although not a primary measure in the study, mood was assessed 
using the Patient Health Questionnaire (PHQ9) (Kroenke, Spitzer, & Williams, 2001), a 
nine item self-report measure assessing symptoms of depression. The measure has been 
shown to be a reliable and valid measure of depression severity and is used routinely in 
NHS primary care settings.  
Disability (see Appendix S): The level of disability in participants due to MS was assessed 
using the Guys Neurological Disability Scale (GNDS; Sharrack & Hughes, 1999). It is a 
MS related disability measure which correlates highly with objective measures of MS 
disability and has excellent psychometric properties (Sharrack & Hughes, 1999)  
Quality of Life (see Appendix T): Quality of life was measured using the Quality of Life 
Index (QLI; Ferrans & Powers, 2007). This measures quality of life in terms of how 
satisfied the participant is with different areas of their life, and also how important the 
participant rates each of these areas. The QLI has been used in studies of various physical 
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health conditions (including a version tailored to MS, which was used here) demonstrating 
good levels of reliability and validity (Stuifbergen, 1995) 
Cognition: The two measures of cognitive functioning used in the Hayter et al. study were 
also used here. These were the Brixton Spatial Anticipation Test (BSAT; Burgess & 
Shallice, 1997) and the Symbol Digit Modality Test (SDMT; Smith, 1982). Both are 
widely used, valid and reliable tests with the BSAT measuring executive functioning and 
the SDMT measuring processing speed and episodic memory. These tests are commonly 
used in the MS research literature.  
Physical functioning: A hand grip dynamometer was used to measure physical grip 
strength following a similar protocol to the Hayter et al. study and developed by Rode, 
Salkovskis, and Jack (2001) in a study of chronic pain.  
Misperception and misattribution (see Appendix N): Misperception of performance on the 
cognitive and physical tasks was assessed using a similar measure to the one developed in 
the Hayter et al. study. Following the physical and cognitive tasks, participants were asked 
to evaluate how well they felt they performed compared to other people with MS on a scale 
from -50 (“Extremely badly in comparison to others”) to +50 (“Extremely well in 
comparison to others”). They then completed a measure of how much better they felt their 
performance on the tasks would have been if they did not have MS, from 0 (“No better”) to 
100 (“Very much better”).   
3.3.4 PROCEDURE 
In Study 1, participants initially completed the assessment of physical and cognitive 
functioning before completing subjective ratings of their performance. Following this, 
participants completed the GNDS, QLI, PHQ9, and SHAI. The sessions took 
approximately 1 hour.  
Participants scoring below 18 on the SHAI then received feedback on their scores. Those 
scoring above 18 were offered the opportunity to take part in Study 2. If participants 
declined treatment or were not eligible then their scores on the measures were fed back to 
them and alternative treatment options discussed. 
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Participants who agreed to take part Study 2 were given a second set of baseline measures 
(SHAI and PHQ9) to complete one week later and bring to their initial treatment session in 
two weeks time. Following the individual baseline period, CBT-HA was delivered over six 
weekly 60 min treatment sessions delivered in the participant’s home. The cognitive model 
of health anxiety posits that anxiety arises from the interpretation of normal bodily 
variations as signs of severe illness (in this case an MS relapse) leading to safety seeking 
behaviours, hypervigilance, physiological arousal etc., that in turn maintain their 
symptoms. Thus a defining element of CBT-HA is helping the patient develop a belief in 
an alternative explanation for their symptoms (i.e., that they are due to anxiety) rather than 
one of having a serious illness. This is done through behavioural experiments whereby they 
test out the utility of their avoidance or safety seeking behaviours in order for them to 
ultimately drop these behaviours and so reduce their anxiety.  In Study 2 a particular 
treatment strategy was to use the data provided by them in Study 1 to compare their 
perceived performance on the cognitive and physical tasks with data from their actual 
performance (idiosyncratic elements of treatment are presented in the case descriptions 
below). In doing so it was hoped they would re-appraise their performance as well as their 
cognitive and physical functioning. At each treatment session participants completed the 
PHQ9 measure of mood and the VSHAI measure of health anxiety. At the end of treatment 
participants completed the SHAI, QLI and PHQ9 before being offered a follow-up session 
in three months time. 
3.3.5 STATISTICAL ANALYSIS 
The effect sizes in the Hayter et al. study, as measured by Cohen’s d (Cohen, 1992) ranged 
from 1.54 (for difference in QLI between health anxious and non health anxious RRMS 
patients) to 1.40 (for the difference between how much health anxious patients attributed 
their task performance to MS compared to non health anxious patients). Given such large 
effects, and setting an acceptable power at 0.8, a sample of 16 participants was needed to 
detect a significant difference between the two groups in Study 1. Where parametric 
assumptions were met, parametric analysis was conducted with Bonferroni corrections 
where appropriate to control Type I error when multiple comparisons were made. For 
instances where parametric test assumptions are not met, Wilcox (2012) recommends using 
modern robust alternative tests that are not susceptible to violations of assumptions (see 
also Erceg-Hurn and Mirosevich (2008)). These include the Yuen-Welch t-test (Ty) which 
75 
 
uses trimmed means and Winsorized variances that are approximated to a Student’s t-
distribution. Monte-Carlo simulation studies have found the test controls Type I error 
while still maintaining power when parametric assumptions have been violated (e.g., 
Keselman, Othman, Wilcox, & Fradette, 2004). The robust alternative tests were 
conducted with the statistical software package R using Wilcox’s Robust Statistic (WRS) 
package.  
For Study 2, visual inspection of the data was used to assess the change in measures from 
baseline and through treatment. Reliable and significant change index (RCI) in scores was 
calculated using the method developed by Jacobson and Truax (1991) whereby the 
difference between the pre- and post-treatment scores on the measures are divided by the 
standard error of the difference between the two test scores (see Appendix G). To calculate 
this index, the pre-treatment standard deviations of the measures from the HiHA 
participants in Study 1 were used as representative of MS patients suffering health anxiety. 
3.4 RESULTS 
3.4.1 STUDY 1 
A median-split of SHAI scores (14.50) was used to assign participants to either HiHA or 
LowHA groups. Table 3.1 shows mean scores for demographic, mood and QLI measures 
across groups. There was no difference between groups in terms of age (t (18) =1.69, 
p>.05, two-tailed); educational level (Ty (13.94) = 0.10, p >.05, two-tailed); physical 
disability (GNDS) (t (18) = 0.24, p>.05, two-tailed); or mood (PHQ9) (t (18) = 1.88, 
p>.05, two-tailed). There was a significant difference between groups on QLI scores (t (18) 
= 4.23, p<.01; Bonferroni p<.05). This effect remained significant even when level of 
physical disability (GNDS) was controlled using ANCOVA (F (1, 17) = 18.51, p<.001). 
The mean (SE) scores for QLI adjusted for GNDS are also presented in Table 3.1. The 
effect size of the difference measured by Cohen’s d was 1.89, 95% CI [0.77, 2.85] 





Table 3.1: Means (Sd) of demographic, mood and quality of life measures across groups.  
 LowHA HiHA 
Age 42.30 (7.27) 36.80 (7.30) 
Education (no. of years) 13.20 (2.39) 13.20 (2.10) 
PHQ9 7.40 (5.58) 12.80 (7.08) 
GNDS 14.20 (3.08) 13.70 (5.83) 
QLI 21.52 (3.63) 15.25 (2.98)* 
QLI – adjusted for GNDS 
(SE) 
21.56 (1.05) 15.20 (1.05) 
* p value <.05, mean difference between LowHA and HiHA  
 
Participants’ scores on the assessment of cognitive and physical abilities are presented in 
Table 3.2. As predicted, there was little difference between groups on any of these 
measures.  
 
Table 3.2: Mean (Sd) scores for the cognitive and physical tasks across groups 
 Cognitive tasks  Physical task 
 SDMT Brixton  Handgrip 
HiHA 55.20 (13.96) 13.10 (6.01)  23.93 (13.11) 
LoHA 52.10 (11.49) 13.20 (3.08)  26.38 (13.89) 
 
Table 3.3 summarises the data from participants’ subjective ratings of their performance on 
the physical and cognitive tasks as well as the extent to which they attributed their 
performance to MS. The mean scores show that LowHA participants rated their 
performance in comparison to others with MS as higher than those in the HiHA group on 
the tasks, and attributed less of their performance to MS. A MANOVA with group as a 
between-subjects factor and ratings of performance on the physical and cognitive tasks as 
dependent variables, showed an overall effect of group (F (2, 17) =4.86, P<.05). 
Subsequent univariate tests showed a significant difference in ratings of cognitive 
performance (F (1, 18) = 7.55, p<.05) but no significant difference in ratings of physical 
performance (F (1, 18) = 1.20, p>.05). The effect size of the difference between groups on 
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ratings of cognitive task performance was d=1.23, 95% CI [0.23, 2.13] suggesting a large 
effect of group on this measure. An independent groups t-test revealed no significant 
difference between groups on how much better they thought they would have performed if 
they did not have MS (t(18) = 0.86, p>.05). 
 
Table 3.3: Participants’ subjective ratings (M (Sd)) of their performance on the cognitive 
and physical tasks and how much better their performance would have been without MS. 
 Perceived performance 
on Handgrip task (-50 to 
+50) 
Perceived performance 
on Cognitive  tasks (-50 
to +50) 
Performance improvement 
if no MS (0 to 100) 
HiHA 4.00 (20.11) -5.00 (12.69) 34.30 (32.05) 
LoHA 14.00 (20.66) 13.00
* 
(16.36) 24.00 (20.11) 
* p value <.05, mean difference between LowHA and HiHA  
3.4.2 STUDY 2 
3.4.2.1 Case descriptions  
See the Procedure section for common elements of treatment (that included discussion of 
their ratings of cognitive and physical performance).  
Patient 1: was a 22 year old woman with a four year old daughter who suffered her first 
MS attack in 2013. The attack had led to paralysis down her left side and required hospital 
admission. While she recovered almost all her physical functioning, she continued to 
notice numbness and tingling in her left arm and leg. At assessment she reported spending 
a great deal of time worrying about the future. In particular, she had images of herself back 
in hospital following a relapse and permanently disabled. Her concern was that if this 
happened, other people would have to look after her and she would be a burden to them. 
The thought that frightened her the most was that she would be unable to care for her 
daughter. She spent long periods of time rubbing her arm to ensure she could still feel 
sensation in it. Whenever she noticed tingling or numbness in her arms or legs she would 
stand up and move around. Her belief was that if she could still move them, she was not 
experiencing a relapse. She would repeat this behaviour frequently during the day.  
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At first, Patient 1 engaged well in therapy but found talking about her fears for the future 
distressing, ending most of the sessions in tears. Through collaborative formulation, she 
recognised that while her images about the future may be accurate (physically disabled), 
the meanings she attributed to them may not be (being a “bad mother”/ “burden” to others). 
She also recognised that her checking behaviour was keeping her preoccupied with 
thoughts about her MS and thus maintaining her anxiety. After guided discovery around 
the value of rubbing her arm during the second session, she spontaneously dropped this 
behaviour before the third session. In Figure 3.1, Patient 1’s VSHAI score can be seen to 
drop following her second session, suggesting a fall in her level of health anxiety. 
However, at the third session a behavioural experiment was developed to help her examine 
what would happen if she dropped her other checking behaviours. While she stated she 
was happy to try the experiment, she did not attend her next scheduled sessions. When she 
was finally seen some weeks later, it emerged she was experiencing flashbacks to her time 
in hospital and being paralysed down her left side. She did not attend any further sessions 
so it was not possible to assess whether she was experiencing a trauma reaction that was 
inadvertently being triggered during treatment sessions that focussed on her MS. The 
implications of this for treatment are discussed below (see Discussion). 
Patient 2: was a 40 year old woman who had been diagnosed with RRMS in 2011. Her 
main symptoms from her first recognised MS attack had been blurring of vision, fatigue 
and pain in her lower back. She had a general distrust of medical professionals; previously, 
when her eldest son was a young child and suffering a life threatening illness, she believed 
it was only through her battling to secure treatment for him that saved his life. At her initial 
assessment, she reported spending long periods worrying about the future. These worries 
were about becoming physically disabled and unable to look after her children. She 
remained vigilant for physical signs she was relapsing and would use the internet to check 
the implications of her symptoms. She would also use the internet to keep abreast of the 
latest research in MS and ensure that she was prepared for her next relapse in terms of 
being able to ask the medical professionals for the most effective treatment. 
Through discussion, Patient 2 recognised that she worried less about her future when she 
was looking after her children and too busy to use the internet. While she did not engage in 
any overt checking of any physical signs of relapse, she did admit to remaining vigilant for 
them. Her treatment sessions focussed on differentiating the process of worry from its 
content and recognising it was the repetitive negative thought processes that were 
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maintaining her distress. Mindfulness techniques were introduced in her third session to 
help her recognise her thoughts when they arrived in her mind, but not to engage in the 
process of worry with them. In Figure 3.1, a change in trend in Patient 2’s VSHAI score 
can be seen following this third session. While she struggled with meditation, she was very 
engaged with the concept and stated she wanted to continue practising following the end of 
treatment. 
Patient 3: was a 43 year old woman diagnosed with RRMS in 2012. She lived with the 
younger of her teenage sons. She was anxious about her future and experienced intrusive 
images of herself in a wheelchair unable to do anything for herself. Her main concern was 
that she would become a burden to others who would eventually resent her. While she had 
discussed her condition with her new partner and he had reassured her he would not 
abandon her, she nevertheless remained concerned that, faced with the reality of the 
condition, this might happen. Most mornings when she awoke she would open her eyes 
and scan her bedroom to ensure that her vision was still working. During a recent 
appointment with a neurologist he had asked her to touch each of her fingers with her 
thumb. She now did this a number of times a day to check that her arms were still 
functioning. 
Guided discovery helped Patient 3 to realise that not all her physical sensations were signs 
of relapse. Psycho-education on the role of adrenaline and “fight or flight” response helped 
her to have more helpful responses to signs of anxiety, rather than worry her disease was 
progressing. At her second treatment session, the value of knowing when a relapse had 
occurred was discussed and hence she devised with the therapist a behavioural experiment 
around reducing her thumb tapping. She did not engage in the behaviour at all over the 
subsequent week and at the fourth session she reported dropping the behaviour completely. 
In Figure 3.1, a change in trend in VSHAI scores can be seen following her second session 
after discussing her perception of physical and cognitive ability with her actual scores at 
assessment and development of her behavioural experiment around thumb tapping. 
Patient 4: was a 43 year old woman who had received her initial diagnosis almost 10 years 
earlier. She experienced intrusive images of herself in the future being unable to care for 
herself. Her worry was that her young daughter would in the future have to look after her 
and resent her for this. Rather than inflict this on her daughter, she believed she would 
have to send her to live with her father and “loose” her daughter. These intrusive images 
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and thoughts occurred often during the day but were mainly associated with times when 
she was alone and had time to think. 
Treatment initially involved exploration her perception of physical and cognitive abilities 
(see Procedure) before exploring how images can be manipulated and changed to become 
less distressing. Treatment then focussed on recognising how the repetitive process of 
worry kept her mind preoccupied on MS and was not necessarily accurate. A pie chart 
technique was used to help her see that she could continue to be a good mother even when 
physically disabled. The concept of “worry time” was presented in her third treatment 
session to help her gain control over her worrying. She reported that “worry time” (setting 
aside a specified period of the day to worry) had a profound effect on her beliefs about 
controlling her worry and resulted in her worrying less about her MS. This is consistent 
with the fall in her VSHAI score in Figure 3.1 following her third treatment session.  
3.4.2.2 Treatment 
The outcome of treatment in Study 2 on measures of health anxiety (SHAI, VSHAI), mood 
(PHQ9) and quality of life (QLI) are presented in Figure 3.1. At the start of treatment all 
participants had SHAI scores above threshold (18) for a diagnosis of hypochondriasis. 
Treatment was tracked each session using the VSHAI and PHQ9. Visual inspection of the 
data for each patient in Figure 3.1 reveals that Patients 2, 3 and 4 showed a level change 
reduction in SHAI score between baseline and the end of treatment which is confirmed by 
their RCI scores (4.26, 4.26 and 4.74 respectively) that were all statistically significant 
(p<.05) (see Appendix G for details of formula for calculating RCI) suggesting a reliable 
and clinically significant reduction in SHAI scores. For Patient 2, this brought her to below 
the threshold for a diagnosis of hypochondriasis (18) while for Patients 3 and 4 their score 
fell to below 10. The RCIs of between 4.26 and 4.74, suggest large effects of treatment and 
but also that Patients 3 and 4 no longer suffered from health anxiety. Inspection of the 
VSHAI scores in Figure 3.1 suggest that the change in trend for these patients happened 
after the second (Patient 3) or third (Patients 2 and 4) treatment session. Patient 1’s SHAI 
score had increased by the end of treatment but the change was not statistically significant. 
The change in trend downwards of her VSHAI score also happened after the second 
session for Patient 1; however this was reversed by the time she attended her fourth 
treatment session.  
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There was also a change in trend and level for PHQ9 scores across all patients. Patients 1, 
3 and 4 showed a reduction in PHQ9 scores by the end of therapy while Patient 2’s PHQ9 
score was already low at baseline. For Patients 1, 3 and 4 the change in trend occurred 
following the first treatment session while for Patient 2 it was after her second session. 
Subjective quality of life ratings for the patients are presented in Table 3.4 with all of the 
patients showing improvements in QLI between baseline and end of treatment. 
 
Table 3.4: Quality of Life Index (QLI) scores for patients at baseline and end of treatment. 
 Baseline Post treatment 
Patient 1 11.16 12.47 
Patient 2 15.59 17.00 
Patient 3 14.41 23.24 




























































Figure 3.1: Ratings of health anxiety (SHAI, VSHAI), mood (PHQ9) and quality of life (QLI) 









3.5.1 SUMMARY OF FINDINGS AND LIMITATIONS 
Study 1 was intended as a preliminary evaluation of the impact of HA on RRMS. It found 
that MS patients with HA rated their QoL lower than those without HA, a difference that 
remained significant even when physical disability was accounted for, and replicated the 
findings from a previous study by Hayter et al. (in process). While a limitation of Study 1 
is its small sample size (which may account for some differences between groups being 
non-significant), the similar pattern of results to those found by Hayter et al. suggest these 
findings are likely to generalise across MS populations. Study 2 reports preliminary 
findings on the impact of CBT-HA for health anxiety in MS. It found that a brief course of 
CBT-HA led to improvements not only in health anxiety but also quality of life and mood. 
To our knowledge, this is the first study examining the treatment of an anxiety disorder in 
MS and represents a significant first step in developing effective treatments for patients 
with health anxiety in this population.  
The findings from Study 1 are consistent with Hayter et al. (ibid) in that the effect-size of 
the difference between low and high levels of health anxiety in terms of QLI was large 
(d=1.89). The same findings across these two studies is unsurprising given previous work 
showing that emotional factors were more predictive of subjective QoL than physical or 
cognitive impairment (Benedict et al., 2005; Dennison et al., 2009; Janssens et al., 2003). 
Given the high rates of health anxiety found in the MS population of between 25 – 30% 
(Hayter et al., in process; Kehler & Hadjistavropoulos, 2009) and the concomitant cost of 
health anxiety to health services (Tyrer et al., 2011a) it would suggest health anxiety 
should be more widely screened for and treated in MS patients.  
Study 1 also found that HiHA participants rated their performance on the cognitive task as 
lower than those in the LowHA group. These results are in line with previous research that 
found anxious and depressed MS patients misperceived themselves as more cognitively 
impaired than their objective test results would suggest (Benedict et al., 2004; Lovera et 
al., 2006; Middleton et al., 2006). The findings are consistent with cognitive accounts of 
anxiety and depression whereby symptoms are maintained through biased appraisals. 
While the difference on ratings of physical performance was large, it was not statistically 
significant. There was also no difference between groups on their attribution of 
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performance to MS. A potential reason for the lack of significant differences compared to 
the finding from Hayter et al., and a further limitation of the study, was how participants 
were allocated to groups. Problems with recruitment meant a median split was used, 
whereas in Hayter et al. the low HA group had SHAI scores <10 and high HA group >18. 
Hence in the current study the difference between the groups in health anxiety was not as 
large, which may have meant the differences between groups on some of the measures was 
not large enough to be detected with the current sample size.  
A limitation of Study 2 was a lack of control for non specific effects of attending therapy. 
The initial plan was to counterbalance the six sessions of CBT with six relaxation training 
sessions but time limitations meant this was not possible. However, given the theoretical 
rationale for the success of CBT-HA, it is not expected that the general findings would 
change with the inclusion of this control. The plan is for participants in Study 2 to receive a 
three month follow-up appointment, so as yet it is unclear whether the rapid improvements 
made by three of the participants remain stable long-term.  
3.5.2 CLINICAL IMPLICATIONS 
The case series suggests that treating health anxiety in MS is possible using an adapted 
CBT approach (CBT-HA) that leads not only to improvements in HA in some patients, but 
also mood and subjective quality of life. The replication of Hayter et al. was driven in part 
to identify targets for treatment during CBT-HA sessions. These were in the form of 
behavioural experiments that included explorations of the meanings of physical and 
cognitive symptoms through discussion of the participants’ objective and perceived scores 
on the cognitive and physical tasks. The use of behavioural experiments in treating anxiety 
is not new (e.g., Salkovskis, Warwick, & Deale, 2003) but the present study builds on 
previous work by suggesting that a focus on specific targets for treatment (misappraisals of 
physical and cognitive functioning) can lead to significant symptom reduction in MS 
patients. 
A large part of the treatment also focussed on participants’ worries about the future; in 
particular what would happen if they became physically disabled. All the patients reported 
intrusive images of them as physically disabled in the future and unable to care of 
themselves. These are consistent with findings from Wells and Hackmann (1993) that 
images of a feared future in health anxiety are often associated with fear of abandonment 
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and an underestimation of coping abilities. Physical disability is a potential reality for 
many MS sufferers and for this reason may not represent a viable target for therapist 
treating health anxiety. However, the treatment here focussed on the meanings the 
participants attributed to this dreaded future. Across all four participants it was a concern 
they would become a “burden” to their families. Exploration of these meanings through 
use of Socratic questioning and guided discovery helped them to alter the meaning of the 
images such that while physical disability was a distinct possibility, their belief that they 
would become a “burden” (or a “bad mother”) was not. Furthermore, the direct 
manipulation of an intrusive image by one patient led to reductions in the negative 
emotions associated with it (for review see Holmes and Mathews (2010)). The present case 
series suggests a potential target in therapy is the unique meaning patients attribute to 
intrusive images in order to help them develop strategies to reduce psychological distress.  
For Patient 1 in Study 2, after her third treatment session she reported other images that 
appeared consistent with experiencing a flash-back to her stay in hospital and suggestive of 
a trauma reaction to this. The reason this did not emerge until later in treatment is likely 
due to her avoidance of triggers of re-experiencing and arousal symptoms. When she felt 
more trusting of the therapist this avoidance may have decreased but the triggering of 
symptoms is likely to have led to her disengagement with treatment. Post-traumatic stress 
disorder (PTSD) can present with elements of any of the other anxiety disorders (Butler, 
Fennell, & Hackmann, 2008) with around sixty percent of patients with PTSD meeting 
criteria for at least one other disorder (Kessler, Sonnega, Bromet, Hughes, & Nelson, 
1995). However, care is needed here as an emerging view in the recent literature is that 
intrusive images of past trauma or feared events are not confined to PTSD. Handley, 
Salkovskis, Scragg, and Ehlers (2009) found that the majority of patients screened for 
travel phobia following the London bombings in 2005 also had PTSD symptoms; with 
some of them reporting intrusive trauma memories and hyper-arousal. They suggest that 
while patients may not have met full criteria for a PTSD diagnosis, treatment should 
incorporate elements of PTSD treatment to help patients overcome their re-experiencing 
symptoms (e.g., Ehlers and Clark (2000)). This seems especially relevant to patients with 
RRMS as their initial attack or relapse can happen suddenly with devastating impact on 
physical functioning (as happened with Patient 1) and experienced as a life-threatening 
trauma. The experience of treating Patient 1 suggest clinicians need to be vigilant of PTSD 
symptoms in RRMS patients presenting with psychological complications (even if they do 
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not meet full criteria for a PTSD diagnosis) so they can get the most appropriate treatment. 
Unfortunately for Patient 1, this did not happen and her PTSD symptoms were not 
recognised early enough in her treatment to focus on them rather than health anxiety. If the 
clinician had done so, Patient 1may have remained in therapy. . 
3.5.3 FUTURE RESEARCH 
The similarity of the intrusive images (and to a large part the meanings attributed to them) 
across all of the patients in the present case series is intriguing. Previous research by Berna 
et al. (2011) in patients with chronic pain revealed a wide variation in the content and 
meaning of intrusive of images. The similarities of images found here may have been due 
to the patients’ similar personal circumstances (all mothers with children living at home). It 
remains an empirical question as to whether the similarity of intrusive images found here is 
reported across the MS patient population more generally. If so, future research might 
consider whether the similarities are accounted for by an aspect of MS or its interaction 
with cognitive processes involved in the development and maintenance of health anxiety 
(or anxiety disorders more generally). The extent to which these images are malleable 
through therapy is also a question for further research. Here the meanings of the negative 
images were successfully targeted but other approaches (such as imagery rescripting or 
retraining; Holmes, Arntz, and Smucker (2007)) may lead to even greater therapeutic 
gains.   
In Study 1, QoL was lower for MS patients with HA compared to the non-HA patients and 
findings support an improvement following treatment (Study 2). These findings suggest 
that health anxiety has a direct negative impact on QoL, but it remains unclear which 
specific mechanisms are involved. Future research might consider whether it is behavioural 
(e.g., safety seeking behaviours) or cognitive (e.g., negative intrusive thoughts/images) that 
are most responsible for reduced QoL and help to prioritise targets for treatment.          
3.5.4 CONCLUSIONS 
The findings from this research partially support the findings from Hayter et al. (in 
process) where in MS patients, health anxiety reduces quality of life, over and above their 
level of physical or cognitive disability. Furthermore, they see their cognitive functioning 
as more impaired than it actually is. Psychological therapy led to improvements in HA and 
87 
 
QoL but without a control group it is unclear whether CBT-HA directly led to these 
improvement or whether some non-specific element of therapy was the cause of these 
improvements. Also, the small numbers of patients treated means caution is needed in 
generalising these findings more widely. Nevertheless, given the high prevalence rate of 
health anxiety in this population, and the economic burden to health care services of 
patients suffering health anxiety, Study 2 suggests that a brief CBT intervention that targets 
misappraisals of cognitive and physical performance as well as intrusive imagery about 
their feared future, could improve MS patients’ wellbeing. The findings pave the way for 
larger, controlled studies to demonstrate the effectiveness of this type of intervention.  
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 4 Executive Summary 
Relapsing and Remitting Multiple Sclerosis (MS) is the most common form of MS. 
Patients have episodes of illness followed by periods of remission where symptoms fade 
away either partially or completely. Understandably, many patients can become anxious 
about when their MS will return or get worse. However, some symptoms of anxiety 
(problems with concentration, memory, feeling tired etc.) appear similar to those of MS 
and can lead to patients worrying that their MS is returning or getting worse when it is not. 
This worry then makes the anxiety symptoms worse which in turn makes the worry about 
their MS worse leading to a viscous cycle that reduces their quality of life, over and above 
the effects of their MS. This is important as healthcare costs increase when patients present 
to services believing their symptoms are signs of serious illness/relapse when in fact they 
are the symptoms of anxiety.  
The process that maintains the anxiety can be explained by the cognitive model of health 
anxiety. Previous research by Hayter et al. used standardised measures to assess MS 
patients’ mental abilities, quality of life, level of health anxiety and physical grip strength, 
as well as their perceptions about their performance on these measures. They found that 
MS patients with high levels of health anxiety perceived themselves as performing worse 
than MS patients with low health anxiety on the measures of physical and mental ability 
and attributed their perceived poor performance to their MS rather than anxiety. The high 
health anxious patients were also more likely to view symptoms that could have been 
caused by anxiety as being their MS and rated their quality of life as worse than patients 
with low health anxiety. These findings suggest that Cognitive Behaviour Therapy (CBT) 
might be helpful for patients with high levels of health anxiety by targeting their mis-
attribution of poor performance and symptoms. This is done by getting patients to compare 
how poorly they thought they did with their actual performance on these tasks as a way of 
helping them to view their symptoms as anxiety that can be treated – rather than their MS.  
This research study was in part a replication of the study by Hayter et al. in that 10 patients 
with high levels of health anxiety were compared with 10 low in health anxiety on 
standardised measures of their quality of life (QoL), cognitive and physical tasks as well as 
how the patients themselves viewed their performance on these tasks. Study 1 replicated 
the findings from the Hayter et al. study: participants with high levels of health anxiety 
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rated their QoL as lower than those low in health anxiety even when their level of physical 
disability was accounted for. The health anxious patients also thought their performance on 
tasks of mental ability was significantly lower; even though it was the same as those in the 
low health anxious group.  
In Study 2, four of the participants who were in the high health anxiety group from Study 
1, went on to receive six sessions of CBT. Before treatment all four had a score on the 
Short Health Anxiety Inventory that would indicate a diagnosis of hypochondriasis /health 
anxiety. Following treatment, two of the participants displayed a dramatic reduction in 
their level of health anxiety suggesting they were no longer anxious about their health. A 
third patient made a significant reduction in her level of health anxiety to below the 
threshold for a diagnosis. The final patient’s level of health anxiety went up, but this was 
most likely due to undiagnosed trauma related to her first MS episode affecting her level of 
anxiety. Three of the patients showed significant improvements in mood, with the fourth 
already having a low score on a measure of mood prior to treatment. All four participants 
showed improvement their self-rated quality of life.  
The findings from this research are consistent with the findings from previous research that 
showed that when MS patients suffer from health anxiety it reduces their quality of life, 
over and above their level of physical disability. Furthermore they see their mental abilities 
as more impaired than they actually are. Given the high prevalence rate of health anxiety in 
this population, and the economic burden to health care services of patients suffering 
health anxiety, Study 2 suggests services should offer brief CBT interventions that could 





 5 Reflective Narrative 
Having completed a Ph.D. over ten years ago and my entire subsequent career being 
involved in research (either University or Industry based), I was not intimidated at the start 
of training by the research component of clinical training. However, in retrospect this was 
probably naive as I found completion of the research projects – in particular the Service 
Improvement Project and Main Project – some of the most stressful research work of my 
career to date. The problems arose mainly from navigating the complexities and 
practicalities of conducting research within the NHS (something I had no experience of 
before) rather than struggling with any theoretical or methodological principals. However, 
facing these challenges and overcoming them have led to a great deal of learning on my 
part and leave me feeling well equipped and enthusiastic to continue with research in the 
NHS in whatever future role I have as a clinical psychologist. The first project I tackled 
was an ill-fated Service Improvement Project (SIP). 
5.1 SERVICE IMPROVEMENT PROJECT 
My initial Service Improvement Project was chosen because I had the good fortune of 
being involved during my first placement (working age adults) with a bipolar group. The 
group had received much anecdotal evidence that it was having a major impact on the lives 
of those patients that attended. However, no formal evidence had been accrued that the 
group facilitator could take to commissioners to ensure it could continue to be funded. 
Hence I suggested conducting focus groups with patients who attended the bipolar group. I 
wrote up the proposal and developed the discussion guide for the focus group, with input 
from the clinical psychologist who facilitated the Bipolar group to ensure it asked the 
questions she wanted answered. Permission was sought from the relevant Trust’s Research 
and Development (R&D) department and invitation letters sent out to patients. Everything 
had been well planned and a large amount of time and effort had been put into the project. 
However, when the time for the focus groups arrived, only two people turned up – even 
though we had received confirmations from many more.  
This was a harsh lesson in the realities of working with this patient group and in the NHS 
more generally. The nature of bipolar disorder is unpredictable and many patient struggle 
to maintain consistency from day to day (helping patients to gain some semblance of 
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control had been a large part of the group’s content). Hence my field supervisor did not 
express dismay when so few attended the focus group. I also wondered whether the fact we 
were not compensating patients for attending the group may have led to them not coming; 
but this view was disconfirmed later through the willingness of patients to give their time 
freely in my Main Project.  I did consider re-arranging the focus groups and to try again 
with the most recent cohort of patients. However, after weighing up the risk of arranging 
another focus group that could fail against the time left before submission, I decided to 
start again with a new project.   
The second SIP I embarked on was with the Neurodevelopmental clinic (NDC) based in 
the CAMHS team in Marlborough and Swindon. The Trust’s clinical lead for ASD was my 
placement supervisor and she wanted an audit of the NDC to ensure it was meeting the 
targets set out in the NICE guidance. She also had a number of service planning questions 
she wanted answering from the audit that had to be incorporated into the data collection 
plan.  
While it was felt that developing a Patient Information Leaflet (PIL) was beyond the scope 
of the project at this time, developing guidance for its content based on feedback from 
patients who had attended the clinic would be possible. The questionnaire used in the SIP 
was based on a previous incarnation used to survey parents when the clinic was geared 
towards the old care pathway. In discussion with the clinical lead, I developed further 
questions relevant to the new care pathway and to investigate patients’ information needs.  
The data collection for the audit took much longer than anticipated due to their being no 
mechanism in the clinic to capture the data pertinent to the audit questions. As a result, I 
had to interrogate individual electronic records and hand input the data into a spreadsheet. 
This experience directly led to one of the recommendations of the SIP: that the NDC 
incorporates NICE audit tools to speed up data analysis. The feedback from the Trust’s 
clinical lead for ASD on the findings from the SIP was positive and she feels it will help 
with service planning. She has also asked that I present the findings to service and audit 
managers at the NDC review meeting in July 2014 to maximise the exposure of the 
findings.  
The project was successful to a large extent because it answered the relevant questions. 
This was achieved through careful elicitation of needs from the Trust’s ASD lead. This 
process also helped structure the data collection so that only the relevant data was extracted 
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from the patient record and reduced the data collection (even though this still took a 
considerable amount of time). Reflecting on the process, the only change I would make 
would be to follow up the patient survey with telephone calls as opposed to letters. This 
was done in a similar study published recently and their response rate was considerably 
higher. I was glad of the experience of conducting a service audit and testing the output 
against national guidelines. This is likely to increasingly form part of my role as I progress 
in my career. Fortunately, the service performed well. I am not sure how it would have felt 
to feed back poor results to a team I admired and enjoyed working with, especially given 
that I was a trainee. When qualified, I think that the same skills utilised in my 
neuropsychology placement, where I had to feed back to patients poor results from their 
cognitive assessment, will stand me in good stead when I have to let teams I work with and 
care about know that their performance needs to improve.  
Having to start a new project from scratch meant that the Gantt chart for my research 
projects was now very much behind schedule. In the original Gantt chart, the second 
project I had planned to complete was my Main Project. However, given the difficulties 
with the process for obtaining ethical approval I had to turn my attention to my Literature 
review. 
5.2 LITERATURE REVIEW 
As an intermittent sufferer, I was keen to base my literature review on insomnia: in 
particular the cognitive processes involved in its maintenance. I had also become intrigued 
by transdiagnostic approaches that posit common cognitive processes across disorders. I 
wondered whether it would be possible to synthesise the research literature to see if any 
transdiagnostic process could account for sleep problems. The most likely candidates were 
worry and rumination.  It was through discussion with my research supervisor (Paul 
Salkovskis) that the topic expanded to include chronic pain with co-morbid insomnia. The 
original plan was to assess whether worry could be differentiated from rumination in 
insomnia and whether the same processes were responsible for pain-related insomnia. I 
have a great deal of experience writing literature reviews as a post-doctoral researcher so I 
did not have much problem marshalling the evidence and synthesising the findings. A 
metaphor I used during the writing of my Ph.D. was of a needle and thread that pulls all the 
pieces of the thesis together into a coherent whole. However, given the wide ranging nature 
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of the topics covered (insomnia, chronic pain, worry and rumination) developing a 
coherent narrative was difficult. This was clear after Paul read the first draft. While all the 
pieces needed for the review were there, it lacked coherence. While Paul suggested 
outlining the structure more clearly at the beginning of the review, careful thinking around 
the arguments I wanted to present meant a complete overhaul of the narrative arc of the 
review. While this did not involve any re-writing, it did mean changing the order of 
sections and including connecting paragraphs/sentences between them.  
In most of my previous research, the literature review has been a prelude to something else 
(most usually data collection and analysis) rather as an end in itself. Here though, the 
review highlighted areas for potential new research and implications for treatment. Given 
the difficulties I have encountered collecting patient data in the NHS, I feel that literature 
reviews of this sort can compliment and provide an alternative to more empirical research 
work of the type embodied in my Main Project. 
5.3 MAIN PROJECT  
As I had done many experimental and cross-sectional studies in previous research roles, I 
wanted my Main Project to include a treatment case series. I also thought that this might be 
more tractable as it would not require large numbers of participants. In the end this was 
irrelevant as the project incorporated both a cross-sectional and case series element. The 
supervisor for my main project was again Paul Salkovskis and it was at his suggestion that 
I replicate Amy Hayter’s study as well as evaluating treatment for health anxiety in 
Multiple Sclerosis (MS) patients. This seemed sensible and would ensure there was a 
fallback position in case of delays. The project also seemed feasible as Dr Leon Dysch in 
the Community Neuro and Stroke Service in Bath thought (at that time in mid 2012) there 
would be no problem accessing sufficient numbers of patients with relapsing and remitting 
MS. 
The original design of the project was to control for the non standard effects of attending 
therapy by having patients also receive six sessions of relaxation training (RT) (as well as 
CBT) with treatment order counterbalanced – following an ABAC alternating treatment 
case series design with three month follow-up. This meant that patients could potentially 
be in treatment for 16 weeks with a further follow-up session three months after the end of 
treatment. The total length of time for this part of the study would have been seven months. 
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To have any hope of completing this on time I needed to have ethical approval in place by 
the beginning of my third year of training and the start of my placement with Leon Dysch. 
In retrospect, I feel I should have contacted the relevant Trust’s R&D department about 
ethics much earlier to get their help navigating the ethics application process. However, it 
later transpired that even they gave inaccurate information about the NRES requirements.  
I found completing the ethics application tortuous as it felt like I was answering the same 
questions over and over. Perhaps because of this it took much longer to complete than it 
should have done. However, now I have completed the process I feel confident it will be a 
much quicker process next time. As the treatment element of the research was case studies, 
both myself and Paul believed that ethical approval was not necessary, as it would be 
routine care; ethical approval would only be required for the cross-sectional part of the 
research. However, I thought that to place this element of the research in context and 
provide a rationale for replicating a previous study, the treatment element would be 
included in the application form. I also put the application forward for proportionate ethical 
review as many of my peers had done so successfully. 
At the initial screen by NRES over the phone, the application was accepted for 
proportionate review and sent to the Brighton and South Coast Ethics Committee. I was 
sent a time that I should make myself available over the telephone if the committee needed 
to phone me to answer any questions they had. As I heard nothing on the day of the 
meeting I assumed there was no problem. I then received a message two days later saying 
they were trying to contact me. When I phoned them back they said that I had been given 
the wrong time and date. Their question was about the lack of a Participant Information 
Sheet (PIS) for the treatment phase of the study. I replied that I did have one but as it was 
routine treatment, I was not seeking ethical approval for this part of the study. I was told 
that this was not the case, I needed to get approval. If I had been available to send them the 
PIS then they did not see a problem, but as they did not have this they had sent the 
application back for a full committee hearing. This was in September 2013 and I was 
rapidly approaching the deadline for when the study needed to begin.  I then had to wait for 
a month, unable to make any representation to NRES to clarify the matter raised at 
proportionate review. When my full committee meeting took place I was told that I could 
telephone in to the meeting to answer their questions. When I did this, I waited on hold for 
45 minutes with no-one telling me whether or when I would get to speak to the committee. 
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It transpired that they were not aware I was using the teleconferencing facility and their 
main concern with my application?  I did not have a PIS for the treatment phase of the 
study.  
This was probably the lowest point in my training course and one of the most stressful 
periods I have ever encountered. I finally gained ethical approval two months later but now 
had no chance of completing the project as planned. It then became apparent that the 
criteria for seeing MS patients in the Community Neuro and Stroke Service had changed in 
the interim period since planning the project and the majority of them were no longer seen 
in the service. The best source of potential participants was the MS nurse specialist, but she 
worked for the Royal United Hospital Trust in Bath, so I had to seek further R&D approval 
from that Trust. All of which meant further delay to recruitment. Another avenue I pursued 
was contacting a local charity organisation: the MS Therapy Centre in Warminster. They 
were very happy to take part and in the end were able to recruit five patients to the study. I 
also sought help from the Bristol and Avon MS (BrAMS) centre which are part of the 
North Bristol NHS Trust (NBT) and thus required approval from their R&D department. 
At the time of writing, NBT have still not processed my request – five months after making 
it.  
By the time I started recruitment it was December 2013 and it would be impossible for 
patients to receive both treatments (CBT and RT) before the deadline of May. In a meeting 
with Paul and Leon it was decided to titrate down the treatment to just include the CBT 
element while recognising the threat to validity of making such a change. Originally, all 12 
of the participants in the high health anxious group would receive treatment so that the 
findings could be converted into an open trial. In the end only 6 participants met inclusion 
criteria of whom 4 agreed to take part in treatment. For the cross-sectional part of the 
study, recruitment went well at first with almost everyone I contacted agreeing to take part. 
However, by the time I had 18 participants, I had run out of people to contact. While I 
phoned and emailed the NBT R&D office I got nowhere with finding out what had 
happened to my application for clearance.   
In the end, I managed to get 20 participants, four short of the total I had hoped for. While 
this was a small sample size, my hope was that the effect sizes I was attempting to detect 
were large enough that this would not be a problem. To counter problems with meeting the 
assumptions of parametric tests, I researched the modern robust alternatives developed by 
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Rand Wilcox and colleagues. In the end, only one of the measures distributions did not 
meet the assumptions for parametric testing,  but learning about the robust alternative tests 
and using R (statistical software package) was a positive learning experience and has 
provided me with a greater range of options for sophisticated data analysis in future 
research. 
What I have learned from this experience is that the NRES ethical clearance process is 
quite possibly not fit for purpose. It has become too complicated, with many people in 
Trusts’ R&D offices not knowing what the requirements are and giving erroneous advice. 
However, this is the context we work in and in future I will not underestimate the time 
needed to steer through this process.  While I feel I have learned a number of valuable 
lessons with regards to NHS research the main area of research methodology that I had not 
encountered before clinical training was the single case design. 
5.4 CASE STUDIES 
Having little prior experience of single case experimental designs, I found this 
methodology slightly intimidating at first. I initially thought it required a great deal of 
planning. Also, many clinicians in the region do not regularly work in this way or utilise 
patient measures as part of routine assessments: making baseline measurement difficult. 
However, as I have progressed through training, I found I needed to be more assertive 
about this with supervisors and it now forms part of my own routine practice. This will 
continue in my future career. However, the greatest learning I received in this regard was 
through the case series I completed as part of my main project. Here I used multiple 
baseline measures, process measures during treatment with planned three month follow up 
measures. I learnt how to visually inspect data to assess changes in level and trend and also 
researched ways to assess reliable and significant change in these measures; it helped me 
develop meaningful inferences about the progress patients made following treatment. 
Regardless of the research I become involved with in the future, the case study is 
something that can always form part of my practice and can provide potential avenues to 
disseminate interesting findings from routine practice.  
In conclusion, I have been conducting psychological research for most of the last 15 years 
and I hope to continue to do so as I move forward with my career. While the mainstay of 
this is likely to be in the first instance case studies, I hope as I settle into my role as a 
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clinician to continue to be involved in more large scale academic research. This could be 
through collaborations with University departments (either through funded research or 
supervising trainee research projects) and NHS research. In the past I have successfully 
applied for research grant money to conduct research within the NHS (even though I left 
the team to start the clinical training course before the project started) and I would like to 
continue to pursue these avenues of funding in the future – perhaps in collaboration with a 
University. In whatever guise it may take, I will continue to be involved in research as I 





Appendix A NICE Criteria for Autism diagnostic assessment for children and 
young people 
AUTISM DIAGNOSTIC ASSESSMENT FOR CHILDREN AND YOUNG PEOPLE 
Criterion 1 The autism diagnostic assessment should be started within 3 
months of the referral to the autism team. 
Exceptions None 
Guideline reference 1.5.1 
Definitions None 
Criterion 2 Every diagnostic assessment should include: 
 detailed questions about parent’s or carer’s concerns and, 
if appropriate, the child’s or young person’s concerns 
 details of the child’s or young person’s experiences of 
home life, education and social care 
 a developmental history, focusing on developmental and 
behavioural features consistent with ICD-10 or DSM-IV 
criteria 
 assessment (through interaction with and observation of 
the child or young person) of social and communication 
skills and behaviours, focusing on features consistent with 
ICD-10 or DSM-IV criteria 
 a medical history, including prenatal, perinatal and family 
history, and past and current health conditions 
 a physical examination  
 consideration of the differential diagnosis 
 systematic assessment for conditions that may coexist 
with autism 
 development of a profile of the child’s or young person’s 
strengths, skills, impairments and needs that can be used 
to create a needs-based management plan, taking into 
account family and educational context 
 communication of assessment findings to the parent or 
carer and, if appropriate, the child or young person. 
Exceptions None 
Guideline reference 1.5.5 
Definitions DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th 
edition; ICD-10: International Statistical Classification of Diseases and 
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Related Health Problems, 10th Revision.  
Criterion 3 A general physical examination should be performed, looking 
specifically for: 
 skin stigmata or neurofibromatosis or tuberous sclerosis 
using a Wood’s light 
 signs of injury, for example self harm or child maltreatment 
 congenital anomalies and dysmorphic features including 
macrocephaly or microcephaly. 
Exceptions None 
Guideline reference 1.5.6 
Definitions None 
COMMUNICATING THE RESULTS FROM THE AUTISM DIAGNOSTIC ASSESSMENT 
Criterion 4 Parents or carers and, if appropriate, the child or young person 
should be provided with a written report of the autism diagnostic 
assessment. This should explain the findings of the assessment 
and the reasons for the conclusions drawn. 
Exceptions None 
Guideline reference 1.8.4 
Definitions None 
Criterion 5 Information, including the written report of the diagnostic 
assessment, should be shared with the GP. 
Exceptions None 
Guideline reference 1.8.5 
Definitions None 
Criterion 6 For children and young people with a diagnosis of autism, a follow-
up appointment should be offered with an appropriate member of 
the autism team within 6 weeks of the end of the autism 




Guideline reference 1.8.8 
Definitions Further discussion could be about the conclusions of the assessment 





Appendix B NICE Criteria for ADHD in children and young people  
 
Criterion 1 
For a diagnosis of ADHD, symptoms of 
hyperactivity/impulsivity and/or inattention should: 
 meet the diagnostic criteria in DSM-IV or ICD-10 
(hyperkinetic disorder) and  
 be associated with at least moderate psychological, social 
and/or educational or occupational impairment based on 
interview and/or direct observation in multiple settings, 
and 
 be pervasive, occurring in two or more important settings 




Definitions A diagnosis of ADHD should only be made by a specialist 
psychiatrist, paediatrician or other appropriately qualified healthcare 
professional with training and expertise in the diagnosis of ADHD. 
See Appendix I for DSM-IV and ICD-10 diagnostic criteria. 
The ICD-10 exclusion on the basis of a pervasive developmental 
disorder being present, or the time of onset being uncertain, is not 
recommended. 
Criterion 2 
As part of the diagnostic process, include an 
assessment of the person’s needs, coexisting 
conditions, social, familial and educational 
circumstances and physical health.  
For children and young people there should also be an 
assessment of their parents’ or carers’ mental health. 




Definitions None  
Criterion 3 
Parents or carers of pre-school children with ADHD 




Definitions Parent-training/education programmes should be first-line treatment 
if the parents or carers have not already attended such a programme 
or the programme has had a limited effect. 
Criterion 4 
If the child or young person with ADHD has moderate 
levels of impairment, the parents or carers should be 
offered referral to a group parent-training/education 
programme either:  
 as a standalone programme or  
 with a group treatment programme for the child or 
young person 
Exceptions A  Child is under school age 
Standard 100% 
Definitions A group treatment programme would involve CBT and/or social skills 
training 
Criterion 5 
In school-age children and young people with severe 








Parents of school-age children and young people with 
severe ADHD should be offered a group-based parent-
training/education programme. 




Drug treatment for children and young people with 
ADHD should always form part of a comprehensive 
treatment plan that includes psychological, behavioural 




Transition to adult services 
Criterion 8 A young person of school leaving age, should be 
reassessed to establish the need for continuing 




Criterion 8a If continuing treatment is needed, arrangements should 
be made for a smooth transition to adult services with 
details of anticipated treatment and services that the 






Criterion 9 During the transition, full information about adult 




Criterion 10 During transition, if the person is aged 16 or over, the 
care programme approach (CPA) should be used as an 





Patients should be offered written information about: 
 their condition 
 the treatment and care they should be offered, 
including being made aware of the ‘Understanding 
NICE guidance’ booklet  
 the service providing their treatment and care. 
Exceptions None 
Standard 100% 
Definitions Patients should be offered written information to help them make 
informed decisions about their healthcare. This should cover the 
condition, treatments and the health service providing care. 
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Information should be available in formats appropriate to the 
individual, taking into account language, age, and physical, sensory 
or learning disabilities. 
Criterion 12 Carers should be offered written information about: 
 the patient’s condition 
 the treatment and care the patient should be offered, 
including being made aware of the ‘Understanding 
NICE guidance’ booklet  
 the service providing the patient’s treatment and 
care. 
Exceptions B.  Where there is no carer involved 
C.  Where sharing information may compromise the patient’s   
confidentiality or wishes 
Standard 100% 
Definitions Carers and relatives should have the opportunity to be involved in 
decisions about the patient’s care and treatment, unless the patient 




Local alternatives to above criteria (to be used where 









Appendix C Data collection tool for ‘Autism: recognition, referral and 
diagnosis of children and young people on the autism spectrum’ 
 
Complete one form for each patient 
Patient identifier: Sex: Age: Organisation/service: 
Ethnicity: 
White Mixed Asian or Asian British Black or Black British Other 
Briti
sh 
 White and 
Black Caribbean 
 Indian  Caribbean  Chinese  
Irish  White and 
Black African 












 White and 
Asian 
 Bangladeshi  Any other Black 
background 
 Not stated            
 
 Any other mixed 
background 
 Any other Asian 
background 
   
 






Autism diagnostic assessment for children and young people 
1 1.1 
Was the autism diagnostic assessment 
started within 3 months of the referral to 





Did the diagnostic assessment include: 
 detailed questions about 
parent’s or carer’s concerns 
and, if appropriate, the child’s or 




 details of the child’s or young 
person’s experiences of home 












 a developmental history, 
focusing on developmental and 
behavioural features consistent 




 assessment (through interaction 
with and observation of the 
child or young person) of social 
and communication skills and 
behaviours, focusing on 
features consistent with ICD-10 




 a medical history, including 
prenatal, perinatal and family 




2.6  a physical examination? 
  
 





 systematic assessment for 





 developing a profile of the 
child’s or young person’s 
strengths, skills, impairments 
and needs that can be used to 
create a needs-based 
management plan, taking into 





 communicating assessment 
findings to the parent or carer 











Did this look specifically for: 
 skin stigmata or 
neurofibromatosis or tuberous 
sclerosis using a Wood’s light? 
  
 
3.3  signs of injury, for example self 




 congenital anomalies and 
dysmorphic features including 











Communicating the results from the autism diagnostic assessment 
4 
4.1 
Were the parents or carers provided 





Was the child or young person provided 




Did this explain the findings of the 








Was the child or young person with a 
diagnosis of autism offered a follow-up 
appointment within 6 weeks of the end 


























Diagnosis and assessment 
1  Is there evidence that the patient’s symptoms 





    
 1.2  ICD-10
1
 
(Data source: patient 
record) 
   
 
  Is there evidence that the level of impairment 
resulting from symptoms of hyperactivity, 
impulsivity or inattention were: 
 1.3.1.3 







on interview and/or 
direct observation 
in multiple settings 
    
                                                 
1
 The ICD-10 exclusion on the basis of a pervasive developmental disorder being present, or the time of onset 
















 1.4  pervasive, 







(Data source: patient 
record) 
    




 the person’s needs 
    
 2.2  coexisting 
conditions 
    
 2.3  social 
circumstances 
    
 2.4  family 
circumstances 
    
 2.4  educational 
circumstances 
    
 2.6  physical health 
(Data source: patient 
record) 
    
 2.7 Have the 
parents/carers had an 
assessment of their 
mental health? 

















3 3.1 If the child is of pre-
school age, have the 
parents/carers been 




  A 1.5.1.3 
  If yes:      
 3.2  was it first-line 
treatment? 
    
 3.3  was it the 
parents/carers’ first 
referral? 
    





4 4.1 If the child/young 
person has moderate 
levels of impairment, 
were the 
parents/carers offered 




   1.5.2.4 
















 4.2  a standalone 
programme 
    
 4.3  with a group 
treatment 
programme for the 
child or young 
person 
    
  If the child/young person is of school-age and 
has severe ADHD, 
 1.5.3.1 
5 5.1  was drug treatment 
offered as the first-
line treatment? 
    





    
7 7.1 Did/does drug 
treatment form part of 
a plan including: 
   1.7.1.4 
7.2  psychological 
advice and 
interventions 
    
7.3  behavioural advice 
and interventions 
    
7.4  educational or 
occupational advice 
and interventions? 
(Data source: patient 
record) 





























Transition from CAMHS to adult services 
8 8.1 Is the young person of 
school leaving age? 
   
1.6.1.1 
 8.2 If yes, have they been 
reassessed to 
establish the need for 
continuing treatment 
into adulthood? 
   
 
 8.3 If no to 8.2, are there 
plans to reassess 
them in the near 
future? 
   
 
8a 8a.1 If continuing treatment 
is needed, have 
arrangements been 
made for a smooth 
transition to adult 
services, including: 
   
1.6.1.1 
 8a.2  anticipated 
treatment required 
    
 8a.3  anticipated services 
required? 
    
9 9.1 If the young person is 
moving from CAMHS 
to adult services, have 
they been provided 
with full information 
about adult services? 

















10 10.1 If the young person is 
aged 16 or over, is 
CPA being used as an 
aid to transfer? 









 their condition 
    
 11.2  the treatment and 
care they should be 
offered 
    
 11.3  including being 





    
 11.4  the service 
providing their 
treatment and care. 
    
  (Data source: patient 
records) 
    
12  





 12.1  the patient’s 
condition 
    
 12.2  the treatment and 
care the patient 
should be offered 
















 12.3  including being 





    




    
  (Data source: patient 
records) 



















13 13.1 Is there a specialist ADHD team?    
1.1.3.1 
 
 If yes, does it run training programmes covering:  
13.2 
 diagnosis 
   
13.3 
 management 
   
 Is the training appropriate for:  
13.4 
 mental health professionals 

















 paediatric professionals 
   
13.6 
 social care professionals 
   
13.7 
 education professionals 
   
13.8 
 forensic professionals 
   
13.9 
 primary care providers 
   
13.10  other professionals who have 
contact with people with ADHD 
   




Appendix E The Neuro-Developmental Clinic (NDC) – Parents’ Survey 
 
Q1.  How old is your child? 
     
0 – 5 yrs 6 - 10yrs 11-15yrs 15-18yrs 
□ □ □ □ 
 
Q2.  Gender of your child? 




Q3. How long did you wait for the appointment? 
    
0-6 months 6-12 months 12-18 months over 18 months 
□ □ □ □ 
 
 
Q4.  Do you think the waiting time was reasonable? 
                   
Strongly agree Agree 
Neither agree 
nor disagree Disagree 
Strongly 
disagree 





Q5.  Did the staff explain the reason why you had an assessment as fully as possible? 
Yes No 
I don’t know/I don’t 
remember 
□ □ □ 
 
Q6. Did the assessment process address all your child’s difficulties? 
  
Strongly agree Agree 
Neither agree 
nor disagree Disagree 
Strongly 
disagree 
□ □ □ □ □ 
 
Q7.  As a parent and/or carer, did you feel that you were encouraged to participate 
in the assessment and that your views, wishes and feelings were actively sought? 
 
Yes No 
I don’t know/I don’t 
remember 
□ □ □ 
 





Q9.  Have you had a feedback session with the clinic yet where a diagnosis for your 
child’s condition was given? 
 
□ Yes (please go to Q10) 
□ No (please go to Q19) 
 
Q10.  Was the outcome of your assessment fed-back to you by one of the clinic team? 
Yes No 
I don’t know/I don’t 
remember 
□ □ □ 
Q11.  What was your child’s diagnosis? 
                   
□ Autism □ 
Speech and language disorder 
□ Asperger’s syndrome □ Global developmental delay 
□ PDD-NOS □ No formal diagnosis 
□ ADHD  
 





Q12.  Did you agree with the diagnosis? 
□ 
 








No – I expected a different diagnosis 
 
Q13.  Were you given the opportunity to discuss your feelings about the diagnosis? 
Yes No 
I don’t know/I don’t 
remember 
□ □ □ 
Q14.  Was the diagnosis explained properly? 
Yes No 
I don’t know/I don’t 
remember 
□ □ □ 
Q15.  Do you think the report from the clinic was useful?    
Yes No 
I don’t know/I don’t 
remember 





Q16.  Were you given information about useful resources? 
Yes No 
I don’t know/I don’t 
remember 
□ □ □ 
Q17. Were you told or given information about local voluntary organisations, social 
support networks, self-help groups and other national services relevant to your 
child’s diagnosis? 
Yes No 
I don’t know/I don’t 
remember 
□ □ □ 
 
Q18. Have you been able to access these resources? 









Q19.  How would you rate the service you and your child received from the clinic? 
      Not 
satisfactory Satisfactory Good Very good Excellent 





Q20.  Would an information leaflet have been helpful before attending the clinic? 
Yes No Not sure 
□ □ □ 
 
Q21.  If yes, what sort of information would you have liked to have known about 
before attending? (Please tick all that are appropriate) 
□ Why you are attending a Neuro-Developmental Clinic 
□ What will happen when you attend the clinic 
□ How long the process of assessment will take 
□ Who you will be seeing in the clinic 
□ What the different outcomes of the assessment might be 
□ How the outcome of the assessment will be feedback to you 
□ What happens after the assessment process 




















































Thank you for completing this questionnaire, your feedback is very much 




Appendix F Results of the Satisfaction Survey sent to parents of children referred 
to the clinic 
Demographics:  
How old is your child? 2 (8-10 yrs) 
8 (11-15 yrs) 
4 (15-18 yrs) 
Gender of your child? 9 Male 
5 Female 
Prior to attending the clinic  
How long did you wait for the appointment? 6 (0-6 months) 
6 (6-12 months) 
1 (12 – 18 months) 
1  (Over 18 months) 
Do you think the waiting time was reasonable? 2 Strongly Agree 
3 Agree 
3 Neither agree or disagree 
5 Disagree 
1 Strongly disagree 
The assessment process  
Did the staff explain the reason why you had 
an assessment as fully as possible? 
 
13 Yes 
1 I don’t know/don’t remember 
Did the assessment process address all your 
child’s difficulties? 
4 Strongly agree 
4 Agree 
2 Neither agree or disagree 
1 Disagree 
2 Strongly disagree 
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As a parent and/or carer, did you feel that you 
were encouraged to participate in the 
assessment and that your views, wishes and 
feelings were actively sought? 
 
11 Yes 
2   No 
1   No response 
How many times have you had to attend the 
Neuro-Developmental Clinic? 
3  (Once) 
4  (Twice) 
1  (Three times) 
3  (Four times) 
1  (Five times) 
2  No response 
Have you had a feedback session with the 
clinic yet where a diagnosis for your child’s 
condition was given? 
 
13 Yes 
1   No response 
The outcome of the assessment  
Was the outcome of your assessment fed-back 
to you by one of the clinic team? 
 
13 Yes 
1   No response 
What was your child’s diagnosis? 
 
3 Autism 
5  Asperger’s Syndrome 
2  ADHD 
3  No formal diagnosis 
1  No response 
Did you agree with the diagnosis? 9  Yes 
2  No strong opinion 
2  No – expected a different diagnosis 
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Were you given the opportunity to discuss 
your feelings about the diagnosis? 
13 Yes 
1   No response 
Was the diagnosis explained properly? 
 
11 Yes 
2   No 
1   No response 




1   No 
1   No response 
Were you given information about useful 
resources? 
8  Yes 
3  No 
1  Don’t remember 
2  No response 
Were you told or given information about local 
voluntary organisations, social support 
networks, self-help groups and other national 
services relevant to your child’s diagnosis? 
 
6  Yes 
5  No 
2  Don’t remember 
1  No response 
Have you been able to access these resources? 7  Yes 
2  No 
5  No response 
Which ones: 4  National Autistic Society 
1  Internet 
1  Google 
Satisfaction with the assessment process  
How would you rate the service you and your 
child received from the clinic? 
3  Excellent 
3  Very good 
2  Good 
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2  Satisfactory 
2  Not satisfactory 
2  No response 
Would an information leaflet have been helpful 
before attending the clinic? 
5  Yes 
5  No 
3  Not sure 
1  No response 
If yes, what sort of information would you 
have liked to have known about before 
attending? 
3  Why you are attending a NDC 
5  What will happen at the clinic 
3  How long the assessment process will take 
3  Who you will be seeing in the clinic 
2  What the different outcomes might be 
2  How the outcome will be fed back to you 
2  What happens after the assessment process 





Appendix G Calculation of Reliable Change Index (from Jacobson & Truax, 1991) 
 
Let X1 = Pretest score; X2 = Posttest Score; rxx = Test-retest reliability of measure; Sdiff = standard 
error of difference between the two test scores; SE = standard error of measurement;  
 
Reliable change index (RC) is calculated by the following equation: 
 




Where   Sdiff = √2(SE)
2 
 
And   SE = Sx√(1-rxx) 
 
An RC larger than 1.96 would be unlikely to occur (p<.05) without actual change. When RC 
exceeds this level the individual can be classified as reliably changed.  
 
The Health Anxiety Inventory has a test-retest reliability of 0.76.  The standard deviation of SHAI 
scores in the HiHA group was 3.04.  Using the above formulae, SE = 1.49 and Sdiff = 2.11. 
 
For  Patient 2 RC = (25 – 16) / 2.11 = 4.26 
 Patient 3 RC = (18 – 9) /2.11 = 4.26 
 Patient 4 RC = (18 – 8)/2.11 = 4.74 
All values are above the cut-off of 1.96 and represent large and significant change (p<.05). 
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Appendix H The International Journal of Cognitive Therapy: Instructions to 
Authors  
 
The International Journal of Cognitive Therapy is the official journal of the International 
Association for Cognitive Psychotherapy (IACP), a professional, scientific, 
interdisciplinary organization whose mission is to facilitate the utilization and growth of 
cognitive therapy as a professional activity and scientific discipline.  The journal is devoted 
to advancing all scientific and clinical aspects of cognitive therapy, including rigorous 
research on cognitive factors and vulnerabilities in psychological disorders, mediating 
processes in treatment outcome, cognitive assessment and treatment, expert perspectives 
on specific clinical problems and populations, and critical issues in translating research to 
practice. We welcome articles of the following types:  
 
1. Empirical research studies of cognitive clinical theories and applications  
2. Theoretical papers and particularly innovative contributions to theory or extensions of 
current theory  
3. Systematic case studies that either extend the current base of knowledge about 
applications of treatments to new clinical problems or that describe new interventions  
4. Reports on new treatment manuals that describe their procedures and contributions in 
relation to previous ones  
5. Literature reviews and meta-analyses  
6. Special thematic issues  
 
All submissions must be made electronically at http://ijct.msubmit.net. Only original 
articles will be considered. Submissions must be double-spaced. Authors should include an 
abstract of fewer than 150 words and must prepare manuscripts according to the format 
and style rules set forth in the publication manual of the American Psychological 
Association. Blind reviews are optional. If authors desire a blind review they should 
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request this in the submission letter. For blind reviews, only a separate coverage page 
should contain identifying information about the authors and their affiliations.  
Tables should be submitted in Excel. Tables formatted in Microsoft Word’s Table function 
are also acceptable. (Tables must not be submitted using tabs, returns, or spaces as 
formatting tools.)  
Figures must be submitted separately as graphic files (in order of preference: TIFF, EPS, 
JPEG, BMP, or GIF) in the highest possible resolution. Figure caption text should be 
included in the article’s Microsoft Word file.  
Permissions: Contributors are responsible for obtaining permission from copyright owners 
if they use an illustration, table, or lengthy quote (100+ words) that has been published 
elsewhere. Contributors should write both the publisher and author of such material, 
requesting nonexclusive world rights in all languages for use in the article and in all future 
editions of it.  
References: Authors should consult the publication manual of the American Psychological 
Association for rules on format and style. Any manuscripts with references that are 
incorrectly formatted will be returned by the publisher for revision.  
Sample References  
Davis, C. G., & McKearney, J. M. (2003). How do people grow from their experience with 
trauma or loss? Journal of Social & Clinical Psychology, 22(5), 477-492.  
Dweck, C., & Wortman, C. (1982). Learned helplessness, anxiety and achievement. In H. 
Kron & L. Laux (Eds.), Achievement, stress, and anxiety (pp. 93-125). Washington, DC: 
Hemisphere Publishing Group.  
Roelofs, J., Meesters, C., Ter Huurne, M., Bamelis, L., & Muris, P. (2006). On the links 
between attachment style, parental rearing behaviors, and internalizing and externalizing 




Appendix I Child and Adolescent Mental Health: Instructions to Authors 
Why submit to Child and Adolescent Mental Health? 
 An international journal with a growing reputation for publishing work of clinical 
relevance to multidisciplinary practitioners in child and adolescent mental health  
 Over 4000 institutions with access to current content, and a further 5000 plus 
institutions in the developing world  
 High international readership - accessed by institutions globally, including North 
America (40%), Europe (37%) and Asia-Pacific (15%)  
 Excellent service provided by editorial and production offices  
 Every manuscript is assigned to one of the Joint Editors as decision-making editor; 
acceptance rate is around 20%  
 Acceptance to EarlyView publication within 2 - 4 months  
 Simple and efficient online submission – 
visit http://mc.manuscriptcentral.com/camh_journal 
 EarlyView – articles appear online before the paper version is published! Click here 
to see the articles currently available;   
 Authors receive access to their article once published as well as 20% discount on 
Wiley-Blackwell publications.  
The journal encourages pre-submission enquiries, which may be sent via the Managing 
Editor at camh@acamh.org.uk 
1.       Contributions from any discipline that further clinical knowledge of the mental life 
and behaviour of children are welcomed. Papers need to clearly draw out the clinical 
implications for mental health practitioners.Papers are published in English. As an 
international journal, submissions are welcomed from any country. Contributions should 
be of a standard that merits presentation before an international readership. Papers may 
assume any of the following forms: Original Articles; Review Articles; Measurement 
Issues; Innovations in Practice. 
 
Original Articles: These papers should consist of original research findings. 
Review Articles: These papers are usually commissioned; they should survey an important 
area of interest within the general field. 
Measurement Issues: These are commissioned review papers that aim to evaluate 
evidence-based measurement issues in child mental health disorders and services. 
Innovations in Practice: Submission to this section should conform to the specific 
guidelines, given in full below. 
2.       Submission of a paper to Child and Adolescent Mental Health will be held to imply 
that it represents an original article, not previously published; that it is not being 
considered for publication elsewhere; and that if accepted for publication it will not be 
published elsewhere without the consent of the Editors. 
3.       Manuscripts should be submitted online.  For detailed instructions please go to:  
http://mc.manuscriptcentral.com/camh_journal and Check for existing account if you have 
submitted to or reviewed for the journal before, or have forgotten your details.  If you are 
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new to the journal Create a new account. Help with submitting online can be obtained 
from Piers Allen at ACAMH (e-mail Piers.Allen@acamh.org.uk) 
4.       Authors’ professional and ethical responsibilities 
 
Disclosure of Interest Form: All authors will be asked to download and sign a full 




Authors are reminded that the Journal adheres to the ethics of scientific publication as 
detailed in the Ethical principles of psychologists and code of conduct (American 
Psychological Association, 2010).  These principles also imply that the piecemeal, or 
fragmented publication of small amounts of data from the same study is not acceptable. 
The Journal also generally conforms to the Uniform Requirements for Manuscripts  of the 
International Committee of Medical Journal Editors (ICJME) and is also a member and 
subscribes to the principles of the Committee on Publication Ethics (COPE).    
Informed consent and ethics approval 
Authors must ensure that all research meets these ethical guidelines and affirm that the 
research has received permission from a stated Research Ethics Committee (REC) or 
Institutional Review Board (IRB) , including adherence to the legal requirements of the 
study county. Within the Methods section, authors should indicate that ‘informed consent’ 
has been appropriately obtained and state the name of the REC, IRB or other body that 
provided ethical approval. When submitting a manuscript, the manuscript page number 
where these statements appear should be given. 
Recommended guidelines and standards 
The Journal requires authors to conform to CONSORT 2010 (see CONSORT Statement) 
in relation to the reporting of randomised controlled clinical trials; also recommended is 
the Extensions of the CONSORT Statement with regard to cluster randomised controlled 
trials). In particular, authors must include in their paper a flow chart illustrating the 
progress of subjects through the trial (CONSORT diagram) and the CONSORT checklist. 
The flow diagram should appear in the main paper, the checklist in the online Appendix. 
Trial registry name, registration identification number, and the URL for the registry should 
also be included at the end of the methods section of the Abstract and again in the Methods 
section of the main text, and in the online manuscript submission. Trials should be 
registered in one of the ICJME-recognised  trial registries: 
 
Australian New Zealand Clinical Trials Registry 
Clinical Trials 
Nederlands Trial Register 
The ISRCTN Register 
UMIN Clinical Trials Registry 
 
Manuscripts reporting systematic reviews or meta-analyses should conform to the 
PRISMA Statement. 
 
The Equator Network is recommended as a resource on the above and other reporting 
guidelines for which the editors will expect studies of all methodologies to follow. Of 
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particular note are the guidelines on qualitative work http://www.equator-
network.org/reporting-guidelines/evolving-guidelines-for-publication-of-qualitative-
research-studies-in-psychology-and-related-fields and on quasi-experimental 
http://www.equator-network.org/reporting-guidelines/the-quality-of-mixed-methods-




5.       Exclusive License Form: Authors will be required to sign an Exclusive License 
Form (ELF) for all papers accepted for publication. Please note that signing of the ELF 
does not affect ownership of copyright in the material. Copies of the form can be 
downloaded here. Online Open is also available as a funded option for those authors 
requiring their article to be published Open Access: please see detailed guidance below. 
6.       Manuscripts should be double spaced and conform to the house style of CAMH.  The 
first page of the manuscript should give the title, name(s) and address(es) of author(s), and 
an abbreviated title (running head) of up to 80 characters.  Specify the author to whom 
correspondence should be addressed and provide their full mailing and email address. 
 
Summary: Authors should include a structured Abstract not exceeding 250 words under 
the sub-headings: Background; Method; Results; Conclusions.   
 
Keywords: Please provide 4-6 keywords (use MeSH Browser for suggestions). 
 
Key Practitioner Message (in the form of 3-6 bullet points) should be given below the 
Abstract, highlighting what's known, what's new and the direct relevance of the reported 
work to clinical practice in child and adolescent mental health. 
7.       Papers submitted should be concise and written in English in a readily 
understandable style, avoiding sexist and racist language.  Original Articles should not 
exceed 5,500 words, including References and Tables.  Occasionally, longer articles 
may be accepted after negotiation with the Editors.  Authors should include a word 
count of their paper.  
8.       Authors who do not have English as a first language may choose to have their 
manuscript professionally edited prior to submission; a list of independent suppliers of 
editing services can be found at 
http://authorservices.wiley.com/bauthor/english_language.asp. All services are paid for and 
arranged by the author, and use of one of these services does not guarantee acceptance or 
preference for publication. 
9.       Headings: Original articles should be set out in the conventional format: Methods, 
Results, Discussion and Conclusion. Descriptions of techniques and methods should only 
be given in detail when they are unfamiliar. There should be no more than three (clearly 
marked) levels of subheadings used in the text. 
 
10.     All manuscripts should have an Acknowledgement section at the end of the main 




Study funding: Please provide information on any external or grant funding of the work (or 
for any of the authors); where there is no external funding, please state this explicitly. 
 
Conflicts of interest: Please disclose any conflicts of interest of potential relevance to the 
work reported for each of the authors. If no conflicts of interest exist, please include an 
explicit declaration of the form: "The author(s) have declared that they have no competing 
or potential conflicts of interest". 
 
Contributorships: Please state any elements of authorship for which particular authors are 
responsible, where contributionships differ between the author group. (All authors must 
share responsibility for the final version of the work submitted and published; if the study 
includes original data, at least one author must confirm that he or she had full access to all 
the data in the study, and takes responsibility for the integrity of the data and the accuracy 
of the data analysis). Contributions from others outside the author group should also be 
acknowledged (e.g. study assistance or statistical advice) and collaborators and study 
participants may also be thanked. 
11.   For referencing, CAMH follows a slightly adapted version of APA Style 
http:www.apastyle.org/. References in running text should be quoted showing author(s) 
and date. For up to three authors, all surnames should be given on first citation; for 
subsequent citations or where there are more than three authors, 'et al.' should be used. A 
full reference list should be given at the end of the article, in alphabetical order. 
 
References to journal articles should include the authors' surnames and initials, the year of 
publication, the full title of the paper, the full name of the journal, the volume number, and 
inclusive page numbers. Titles of journals must not be abbreviated. References to chapters 
in books should include auhtors' surnames and initials, year of publication, full chapter 
title, editors' initials and surnames, full book title, page numbers, place of publication and 
publisher. 
12.   Tables: These should be kept to a minimum and not duplicate what is in the text; they 
should be clearly set out and numbered and should appear at the end of the main text, with 
their intended position clearly indicated in the manuscript. 
13.   Figures: Any figures, charts or diagrams should be originated in a drawing package 
and saved within the Word file or as an EPS or TIFF file. See 
http://authorservices.wiley.com/bauthor/illustration.asp for further guidelines on preparing 
and submitting artwork.  Titles or captions should be clear and easy to read. These should 
appear at the end of the main text. 




Appendix J Behavior Research and Therapy: Instructions to Authors 
. 
INTRODUCTION 
Behaviour Research and Therapy encompasses all of what is commonly referred to as 
cognitive behaviour therapy (CBT). The focus is on the following: theoretical and 
experimental analyses of psychopathological processes with direct implications for 
prevention and treatment; the development and evaluation of empirically-supported 
interventions; predictors, moderators and mechanisms of behaviour change; and 
dissemination and implementation of evidence-based treatments to general clinical 
practice. In addition to traditional clinical disorders, the scope of the journal also 
includes behavioural medicine. The journal will not consider manuscripts dealing 
primarily with measurement, psychometric analyses, and personality assessment. 
 
The Editor and Associate Editors will make an initial determination of whether or not 
submissions fall within the scope of the journal and/or are of sufficient merit and 
importance to warrant full review. 
Contact details 
Any questions regarding your submission should be addressed to the Editor in Chief: 
Professor G. T. Wilson, Psychological Clinic at Gordon Road 
Rutgers 
The State University of New Jersey 







BEFORE YOU BEGIN 
Ethics in publishing 
For information on Ethics in publishing and Ethical guidelines for journal publication 
see http://www.elsevier.com/publishingethics and http://www.elsevier.com/journal-
authors/ethics. 
 
Conflict of interest 
All authors are requested to disclose any actual or potential conflict of interest 
including any financial, personal or other relationships with other people or 
organizations within three years of beginning the submitted work that could 
inappropriately influence, or be perceived to influence, their work. See also 
http://www.elsevier.com/conflictsofinterest. Further information and an example of a 




Submission of an article implies that the work described has not been published 
previously (except in the form of an abstract or as part of a published lecture or 
academic thesis or as an electronic preprint, see  
http://www.elsevier.com/postingpolicy), that it is not under consideration for 
publication elsewhere, that its publication is approved by all authors and tacitly or 
explicitly by the responsible authorities where the work was carried out, and that, if 
accepted, it will not be published elsewhere including electronically in the same form, 
in English or in any other language, without the written consent of the copyright-
holder. 
 
Changes to authorship 
This policy concerns the addition, deletion, or rearrangement of author names in the 
authorship of accepted manuscripts: Before the accepted manuscript is published in an online 
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issue: Requests to add or remove an author, or to rearrange the author names, must 
be sent to the Journal Manager from the corresponding author of the accepted 
manuscript and must include: (a) the reason the name should be added or removed, 
or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from 
all authors that they agree with the addition, removal or rearrangement. In the case 
of addition or removal of authors, this includes confirmation from the author being 
added or removed. Requests that are not sent by AUTHOR INFORMATION PACK 28 
Mar 2014 www.elsevier.com/locate/brat 5 the corresponding author will be forwarded 
by the Journal Manager to the corresponding author, who must follow the procedure 
as described above. Note that: (1) Journal Managers will inform the Journal Editors of 
any such requests and (2) publication of the accepted manuscript in an online issue is 
suspended until authorship has been agreed.  
 
After the accepted manuscript is published in an online issue: Any requests to add, delete, or 
rearrange author names in an article published in an online issue will follow the same 
policies as noted above and result in a corrigendum. 
 
Copyright 
This journal offers authors a choice in publishing their research: Open Access and 
Subscription.  
 
For Subscription articles 
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing 
Agreement' (for more information on this and copyright, see 
http://www.elsevier.com/copyright). An e-mail will be sent to the corresponding 
author confirming receipt of the manuscript together with a 'Journal Publishing 
Agreement' form or a link to the online version of this agreement. Subscribers may 
reproduce tables of contents or prepare lists of articles including abstracts for internal 
circulation within their institutions. Permission of the Publisher is required for resale or 
distribution outside the institution and for all other derivative works, including 
compilations and translations (please consult http://www.elsevier.com/permissions).  
 
If excerpts from other copyrighted works are included, the author(s) must obtain 
written permission from the copyright owners and credit the source(s) in the article. 
Elsevier has preprinted forms for use by authors in these cases: please consult 
http://www.elsevier.com/permissions. 
 
For Open Access articles 
Upon acceptance of an article, authors will be asked to complete an 'Exclusive License 
Agreement' (for more information see http://www.elsevier.com/OAauthoragreement). 
Permitted reuse of open access articles is determined by the author's choice of user 
license (see http://www.elsevier.com/openaccesslicenses). 
 
Retained author rights 
As an author you (or your employer or institution) retain certain rights. For more 
information on author rights for: Subscription articles please see 
http://www.elsevier.com/journal-authors/author-rights-and-responsibilities. 
Open access articles please see http://www.elsevier.com/OAauthoragreement. 
 
Role of the funding source 
You are requested to identify who provided financial support for the conduct of the 
research and/or preparation of the article and to briefly describe the role of the 
sponsor(s), if any, in study design; in the collection, analysis and interpretation of 
data; in the writing of the report; and in the decision to submit the article for 






Funding body agreements and policies 
Elsevier has established agreements and developed policies to allow authors whose 
articles appear in journals published by Elsevier, to comply with potential manuscript 
archiving requirements as specified as conditions of their grant awards. To learn more 




This journal offers authors a choice in publishing their research: 
Open Access 
• Articles are freely available to both subscribers and the wider public with permitted 
reuse 
• An Open Access publication fee is payable by authors or their research funder 
Subscription 
• Articles are made available to subscribers as well as developing countries and 
patient groups through 
our access programs (http://www.elsevier.com/access) 
• No Open Access publication fee 
Reference style 
Text: Citations in the text should follow the referencing style used by the American 
Psychological Association. You are referred to the Publication Manual of the American 
Psychological Association, Sixth Edition, ISBN 978-1-4338-0561-5, copies of which 
may be ordered from http://books.apa.org/books.cfm?id=4200067 or APA Order 
Dept., P.O.B. 2710, Hyattsville, MD 20784, USA or APA, 3 Henrietta Street, London, 
WC3E 8LU, UK. 
 
List: references should be arranged first alphabetically and then further sorted 
chronologically if necessary. More than one reference from the same author(s) in the 




Reference to a journal publication: 
Van der Geer, J., Hanraads, J. A. J., & Lupton, R. A. (2010). The art of writing a 
scientific article. Journal of Scientific Communications, 163, 51–59. 
 
Reference to a book: 
Strunk, W., Jr., & White, E. B. (2000). The elements of style. (4th ed.). New York: 
Longman, (Chapter  
4). 
Reference to a chapter in an edited book: 
Mettam, G. R., & Adams, L. B. (2009). How to prepare an electronic version of your 
article. In B. S. Jones, & R. Z. Smith (Eds.), Introduction to the electronic age (pp. 281–
304). New York: E-Publishing Inc. 
 
Video data 
Elsevier accepts video material and animation sequences to support and enhance your 
scientific research. Authors who have video or animation files that they wish to submit 
with their article are strongly encouraged to include links to these within the body of 
the article. This can be done in the same way as a figure or table by referring to the 
video or animation content and noting in the body text where it should be placed. All 
submitted files should be properly labeled so that they directly relate to the video file's 
content. In order to ensure that your video or animation material is directly usable, 
please provide the files in one of our recommended file formats with a preferred 
maximum size of 50 MB. Video and animation files supplied will be published online in 
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the electronic version of your article in Elsevier Web products, including ScienceDirect: 
http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose 
any frame from the video or animation or make a separate image. These will be used 
instead of standard icons and will personalize the link to your video data. For more 
detailed instructions please visit our video instruction pages at 
http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot 
be embedded in the print version of the journal, please provide text for both the 
electronic and the print version for the portions of the article that refer to this content. 
 
AudioSlides 
The journal encourages authors to create an AudioSlides presentation with their 
published article. AudioSlides are brief, webinar-style presentations that are shown 
next to the online article on ScienceDirect. This gives authors the opportunity to 
summarize their research in their own words and to help readers understand what the 
paper is about. More information and examples are available at 
http://www.elsevier.com/audioslides. Authors of this journal will automatically receive 




Elsevier accepts electronic supplementary material to support and enhance your 
scientific research. Supplementary files offer the author additional possibilities to 
publish supporting applications, highresolution images, background datasets, sound 
clips and more. Supplementary files supplied will be published online alongside the 
electronic version of your article in Elsevier Web products, including ScienceDirect: 
http://www.sciencedirect.com. In order to ensure that your submitted material is 
directly usable, please provide the data in one of our recommended file formats. 
Authors should submit the material in electronic format together with the article and 
supply a concise and descriptive caption for each file. For more detailed instructions 




The following list will be useful during the final checking of an article prior to sending it 
to the journal for review. Please consult this Guide for Authors for further details of 
any item. 
 
Ensure that the following items are present: 
One author has been designated as the corresponding author with contact details: 
AUTHOR INFORMATION PACK 28 Mar 2014 www.elsevier.com/locate/brat 10 
• E-mail address 
• Full postal address 
• Phone numbers 
 
All necessary files have been uploaded, and contain: 
• Keywords 
• All figure captions 
• All tables (including title, description, footnotes) 
 
Further considerations 
• Manuscript has been 'spell-checked' and 'grammar-checked' 
• References are in the correct format for this journal 
• All references mentioned in the Reference list are cited in the text, and vice versa 
• Permission has been obtained for use of copyrighted material from other sources 
(including the Web) 
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• Color figures are clearly marked as being intended for color reproduction on the Web 
(free of charge) and in print, or to be reproduced in color on the Web (free of charge) 
and in black-and-white in print 
• If only color on the Web is required, black-and-white versions of the figures are also 
supplied for printing purposes 
 














Appendix L Main Project: Participant Information Sheet – Study 1 
 
                 
PARTICIPANT INFORMATION SHEET – ASSESSMENT PHASE 
Effects of health anxiety in recently diagnosed Multiple Sclerosis 
Chief Investigator: Dr Neil Carrigan Supervisors:  Prof Paul Salkovskis, Dr Jo Daniels & 
  Dr Leon Dysch 
We would like to invite you to take part in our research study. Before you decide we would like 
you to understand why the research is being done and what it would involve for you. One of our 
team will go through the information sheet with you and answer any questions you have. We 
suggest this should take about 15 minutes. 
Talk to others about the study if you wish. (Part 1 tells you the purpose of this study and what will 
happen to you if you take part. Part 2 gives you more detailed information about the conduct of 
the study).  
Ask us if there is anything that is not clear. 
Part 1: 
What is the purpose of the study? 
I am a Clinical Psychologist in Training at the Department of Psychology, University of Bath. I am 
interested in the effect of anxiety on the quality of life of people recently diagnosed with MS. This 
research project wants to look at the effects of anxiety on physical and mental ability as well as 
how patients think they do on these tasks. We will also measure quality of life. This will tell us 
whether anxiety is affecting these abilities and its impact on patients’ lives. This will hopefully 




Why have I been invited? 
You have been invited because you have recently been diagnosed with relapsing and remitting 
MS. There will be 24 people in total taking part in the study. 
Do I have to take part? 
It is up to you to decide to join the study. If you decide to take part your health care professional 
will pass your details to the research team. We will then contact you, describe the study and go 
through this information sheet. If you agree to take part, we will then ask you to sign a consent 
form.  You are free to withdraw at any time, without giving a reason. This would not affect the 
standard of care you receive.   
What will happen to me if I take part? 
We will invite you to an appointment with the researcher. There you will be asked to fill out some 
questionnaires about: 
 Quality of life  
 How anxious you are about your health 
 Your physical disability due to MS. 
 
Following the questionnaires we will take a measure of physical strength using what is called a 
hand grip dynamometer. This requires you to grip a lever and hold it while a measure is taken on 
a dial. Then we will complete a short task that measures how good your memory is, how quickly 
you can think and make decisions.  
In total the session should take no more than 1 hour.  
Following the testing session we will discuss the results with you and explain what they mean. We 
hope you will find the results personally interesting. If you are anxious about your health we will 
discuss with you the options for treatment and provide a separate information sheet to help you 
decide what you would like to do.  
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you 




Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
If the information in Part 1 has interested you and you are considering participation, please read 
the additional information in Part 2 before making any decision. 
Part 2: 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time and your data will then not be used in the 
study.  
Once you have completed the study all identifiable data will be destroyed but we will retain the 
anonymised data. In the unlikely event that you lose the capacity to make decisions following 
participation in the study we will still retain the anonymised data for analysis. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researcher 
who will do their best to answer your questions (details at the end of this information sheet). If 
you remain unhappy and wish to complain formally, you can do this (eg NHS Complaints 
Procedure). Details can be obtained from the Chief Investigator. 
In the unlikely event that something does go wrong and you are harmed during the research and 
this is due to someone‘s negligence then you may have grounds for a legal action for 
compensation against the University of Bath but you may have to pay your legal costs. The normal 
National Health Service complaints mechanisms will still be available to you (if appropriate). 
Will my taking part in this study be kept confidential? 
The paper copies of the questionnaires and physical/mental ability tasks will be shredded once 
they have been entered onto the secure NHS computers. Your data it will then be anonymised 
with access only to the researcher and the research team. We will keep this anonymous data for a 





What will happen to the results of the research study? 
Following the testing session we will discuss the results with you individually. Once we have 
analysed the data from all participants we will send you a summary of the main findings. This 
summary data may be used in publications arising from the research. None of the data used in 
these publications will be identifiable as you. 
Who is funding this research? 
The research is being funded as part of the researcher’s Professional Doctorate in Clinical 
Psychology at the University of Bath. 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion 
by the Oxford C Research Ethics Committee.   
Further Information and Contact Details 
Further information about taking part in NHS research can be found on the Multiple Sclerosis 
Trust website here:   
http://www.mstrust.org.uk/research/gettinginvolved/clinicalstudies/patientresearch.jsp 
If you would like to speak to me further about this specific research my contact details are: 
Researcher:  Dr. Neil Carrigan  Telephone: 0781 587 0088 
       email:  neil.carrigan@nhs.net 
Address:  Clinical Psychology,  6 West 
Department of Psychology 
   University of Bath 
   Bath 





Appendix M Main Project: Consent Form 
 
Patient Identification Number: 
CONSENT FORM – ASSESSMENT PHASE 
Title of Project: Effects of health anxiety in recently diagnosed Multiple Sclerosis 
Name of Researcher: Dr Neil Carrigan 
Please initial all boxes  
1. I confirm that I have read and understand the patient information sheet (assessment phase) 
dated 11/11/2013 (version3) for the above study.  I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
   
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that data collected during the study, may be looked at by individuals from 
University of Bath, from regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research.  I give permission for these individuals to have access to this 
data. 
 
4. I agree that once I have completed the study, if I lose the capacity of consent, that my data 
will be retained by the researchers for analysis in an anonymised form 
 
5. I agree to my GP being informed of my participation in the study.  
 
6. I agree to take part in the above study. 
  
            
Name of Participant   Date    Signature 
                              
            
Name of Person   Date    Signature  




Appendix N Main Project: Perception of Performance Measures 
 
Perception of Performance 
 
Compared to others with a similar condition to you, how well do you feel you 
performed on hand grip task? (Please tick) 
Extremely 
badly  in 
comparison 
to others 
         Extremely 
well  in 
comparison 
to others 
-50 -40 -30 -20 -10 0 +10 +20 +30 +40 +50 
□ □ □ □ □ □ □ □ □ □ □ 
 
Compared to others with a similar condition to you, how well do you feel you 
performed on cognitive tasks? (Please tick) 
Extremely 
badly  in 
comparison 
to others 
         Extremely 
well  in 
comparison 
to others 
-50 -40 -30 -20 -10 0 +10 +20 +30 +40 +50 
□ □ □ □ □ □ □ □ □ □ □ 
 
How worried were you about your performance on these tasks? (Please tick) 
Not at all 
worried 
         Extremely 
worried 
0 10 20 30 40 50 60 70 80 90 100 
□ □ □ □ □ □ □ □ □ □ □ 
 
How much better would you have performed on the tasks if you did not have MS? 
(Please tick) 
Not better          Very much 
better 
0 10 20 30 40 50 60 70 80 90 100 




Appendix O Data Specification for additional questions the Trust’s ASD lead 
wanted answers for 
 
Total no of referrals  
Dec 2011 - Dec 2012 





  Sex of referrals Male 
  
Female 
    
         











   
         
         
Swindon /Wiltshire (%) 
Swindon 
=  % 
Wiltshire 
= % 
    Profession of Referrer 
        
         Average Time from 




9 days - 6 
months 
6 cases >3 
months 
    
         DNAs (%) 
        Outcome of 1st 
appointment (%) 
        Diagnosis 
        Further assessment 
        Withdrew 
        Type of further 
assessment (%) 
        Cognitive 
        WISC 
        TEAcH 
        WISC & TEAcH 
        School 
        Obs 
        Discussion 
        Emotional 
        One-to-one 
        Self-report 
        Self-report & 1:1 
        Conners’ 
        Parent rated 
        Teacher rated 
        Self-rated 
        No. Of appointments 
        Average 
        Range 
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Time to diagnosis 
(weeks) 
        Average 
        Range 
        Consider 5 longest for 
reasons 
        












        ADHD 
        Attachment 
        Social communication 
        ODD 
        Other 
        None 
        Medications prescribed 
        Destination following 
diagnosis 
        CAMHS 
        Day Unit 
        LD etc 
        Percentage with ADHD 
having parenting 
intervention 
        % with LD 
        % having Ed psych input 
        










        
 
PARTICIPANT INFORMATION SHEET – TREATMENT PHASE 
Effects of health anxiety in recently diagnosed Multiple Sclerosis 
Chief Investigator: Dr Neil Carrigan Supervisors:  Prof Paul Salkovskis, Dr Jo Daniels & 
  Dr Leon Dysch 
We would like to invite you to take part in our research study. Before you decide we would like 
you to understand why the research is being done and what it would involve for you. One of our 
team will go through the information sheet with you and answer any questions you have. We 
suggest this should take about 15 minutes. 
Talk to others about the study if you wish. (Part 1 tells you the purpose of this study and what will 
happen to you if you take part. Part 2 gives you more detailed information about the conduct of 
the study).  













What is the purpose of the study? 
I am a Clinical Psychologist in Training at the Department of Psychology, University of Bath. I am 
interested in the effect of anxiety on the quality of life of people recently diagnosed with MS. This 
research project wants to look at the effects of anxiety on physical and mental ability as well as on 
how patients think they do on these tasks. We will also measure quality of life. This will tell us 
whether anxiety is affecting these abilities and its impact on their lives. If anxiety is affecting the 
patients in this way, then treating it with psychological therapy might improve the patients’ 
overall quality of life. This part of the study will assess how effective the psychological therapy is 
in doing this. 
Why have I been invited? 
You have been invited because you recently took part in the earlier assessment phase of this 
study. At that point we discussed with you that your scores on the Health Anxiety Inventory 
questionnaire suggest you may be anxious about your health.  Because you appear anxious about 
your health we would like to see if treating your anxiety with psychological therapy is helpful. 
Do I have to take part? 
It is up to you to decide to join the study. We will describe the study and go through this 
information sheet. You are free to withdraw at any time, without giving a reason. This would not 
affect the standard of care you receive.   
What will happen to me if I take part? 
If you continue in the study you will be offered up to 6 one hour sessions of psychological therapy: 
cognitive behaviour therapy (CBT)). This is an evidence-based treatment that has been approved 
by NICE (National Institute for Health and Care Excellence) for the treatment of anxiety. Every 
week we will ask you to complete a short set of questionnaires about your mood and level of 
anxiety to monitor how treatment is progressing.  
The researcher will explore with you how your thoughts and the things you are doing are affecting 
your mood and your anxiety about your health. The researcher will work with you to explore 




Some of these sessions will be recorded (either audio or video) to help the researcher, in 
discussions with his supervisor, ensure the best treatment is being delivered to you. The 
recordings will not be used for any other purpose. Once treatment has finished the recordings of 
your treatment will be destroyed. Between sessions you may be asked to complete tasks to help 
with your treatment and complete measures of your mood and anxiety. 
When these sessions have finished we will contact you again in 3 months for a session with the 
researcher to see how you are doing and for you to complete a further set of questionnaires. 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you 
might suffer will be addressed. The detailed information on this is given in Part 2. 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering participation, please read 
the additional information in Part 2 before making any decision. 
 
Part 2: 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw from the study at any time and your data will then not be used in the 
study. You can then discuss with your care coordinator what treatment is most appropriate to 
continue with, if any. Withdrawing from the study will not affect the availability of the standard 
care offered to you. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions (details at the end of this information sheet). If 
you remain unhappy and wish to complain formally, you can do this (e.g., NHS Complaints 
Procedure). Details can be obtained from the Chief Investigator. 
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In the unlikely event that something does go wrong and you are harmed during the research and 
this is due to someone‘s negligence then you may have grounds for a legal action for 
compensation against the University of Bath but you may have to pay your legal costs. The normal 
National Health Service complaints mechanisms will still be available to you (if appropriate). 
Will my taking part in this study be kept confidential? 
All the data recorded as part of your treatment will be kept confidential. Only your direct care 
team will be aware that you are taking part in the study 
It is standard practice to inform your GP of any treatment you are receiving as part of your care. 
What will happen to the results of the research study? 
The data you provided from the testing session and during therapy will be discussed with you 
individually. Once we have analysed the data from all participants we will send you a summary of 
the main findings. This summary data may be used in publications arising from the research. None 
of the data used in these publications will be identifiable as you. 
Who is funding this research? 
The research is being funded as part of the researcher’s Professional Doctorate in Clinical 
Psychology at the University of Bath. 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given favourable opinion 




Further Information and Contact Details 
Further information about taking part in NHS research can be found on the Multiple Sclerosis 
Trust website here:   
http://www.mstrust.org.uk/research/gettinginvolved/clinicalstudies/patientresearch.jsp 
If you would like to speak to me further about this specific research my contact details are: 
Researcher:  Dr. Neil Carrigan  Telephone: 0781 587 0088 
       email:  neil.carrigan@nhs.net 
Address:  Clinical Psychology,  6 West 
Department of Psychology 
   University of Bath 
   Bath 




Appendix Q Short Health Anxiety Inventory adapted for MS patients 
Short Month          Ass/Wk/Sess: 
___ 
HAI 
Each question in this section consists of a group of four statements. Please read each group 
of statements carefully and then select the one which best describes your feelings, OVER 
THE PAST SIX MONTHS.  Identify the statement by ringing the letter next to it i.e., if 
you think statement (a) is correct, ring statement (a); it may be that more than one 
statement applies, in which case, please ring any that are applicable. 
1  (a) I do not worry about my health 
(b) I occasionally worry about my health 
(c) I spend much of my time worrying about my health 
(d) I spend most of my time worrying about my health 
 
2  (a) I notice aches/pains less than other people (of my age) 
(b) I notice aches/pains as much as most other people (of my age) 
(c) I notice aches/pains more than most other people (of my age) 
(d) I am aware of aches/pains in my body all the time 
 
3  (a) As a rule I am not aware of bodily sensations or changes 
(b) Sometimes I am aware of bodily sensations or changes 
(c) I am often aware of bodily sensations or changes 
(d) I am constantly aware of bodily sensations or changes 
 
4  (a) Resisting thoughts of illness is never a problem 
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(b) Most of the time I can resist thoughts of illness 
(c)  I try to resist thoughts of illness but I am often unable to 
(d) Thoughts of illness are so strong that I no longer even try to resist them 
 
5  (a) As a rule I am not afraid that I have a serious illness [other than MS] 
(b) I am sometimes afraid that I have a serious illness [other than MS] 
(c) I am often afraid that I have a serious illness [other than MS] 
(d) I am always afraid that I have a serious illness [other than MS] 
 
6 (a) I do not have images (mental pictures) of myself being ill 
(b) I occasionally have images of myself being ill 
(c) I frequently have images of myself being ill 
(d) I constantly have images of myself being ill 
 
7  (a) I do not have any difficultly taking my mind off thoughts about my health 
(b) I sometimes have difficulty taking my mind off thoughts about my health 
(c) I often have difficulty taking my mind off thoughts about my health 
(d) Nothing can take my mind off thoughts about my health 
 
8 (a) I am lastingly relieved if my doctor tells me there is nothing wrong 
(b) I am initially relieved but worries sometimes return later 
(c) I am initially relieved but the worries always return later 




9  (a) If I hear about an illness, other than MS, I never think I have it myself 
(b) If I hear about an illness, other than MS, I sometimes think I have it myself  
(c) If I hear about an illness, other than MS, I often think I have it myself 
(d) If I hear about an illness, other than MS, I always think I have it myself 
 
10 (a) If I have a bodily sensation or change I rarely wonder what it means 
(b) If I have a bodily sensation or change I often wonder what it means 
(c) If I have a bodily sensation or change I always wonder what it means 
(d) If I have a bodily sensation or change I must know what it means 
 
11 (a) I usually feel at very low risk for developing a serious illness [other than  
  MS] 
(b) I usually feel at fairly low risk of developing a serious illness [other than  
  MS] 
(c) I usually feel at moderate risk for developing a serious illness [other than  
  MS] 
(d) I usually feel at high risk of developing a serious illness [other than MS] 
 
12 (a) I never think I have a serious illness, other than MS 
(b) I sometimes think I have a serious illness, other than MS 
(c) I often think I have a serious illness, other than MS 




13 (a) If I notice an unexplained bodily sensation I never do anything to try and  
  get rid of it 
(b) If I notice an unexplained bodily sensation I sometimes try to get rid of it 
(c) If I notice an unexplained bodily sensation I often try to get rid of it 
(d) If I notice an unexplained bodily sensation I always try to get rid of it 
 
14 (a) My family/friends would say I do not worry enough about my health 
(b) My family/friends would say I have a normal attitude to my health 
(c) My family/friends would say I worry too much about my health 




Appendix R Patient health questionnaire (PHQ9) 
  Over the last 2 weeks, how often have you  
  been bothered by any of the following problems? 


















Nearly       
every 
 day 
1.  Little interest or pleasure in doing things.......……… 0 1 2 3 
2.  Feeling down, depressed, or hopeless.………..…… 0 1 2 3 
3.  Trouble falling or staying asleep, or sleeping too 
much..................................................………..…….. 
 




  2 
 
  3 
4.  Feeling tired or having little energy......……...……… 0 1 2 3 
5.  Poor appetite or overeating.......................……….…    0 1 2 3 
6.  Feeling bad about yourself — or that you are a failure   or have 
let yourself or your family down………………….. 
 






  3 
7.  Trouble concentrating on things, such as reading the newspaper 
or watching television.……………………….. 
 






  3 
8.  Moving or speaking so slowly that other people could have 
noticed?  Or the opposite — being so fidgety or restless that you 


















9.  Thoughts that you would be better off dead or of hurting 









                                                   Column totals          ___   +     ___  +  ____  +    ___  
                                                                                                






























Appendix T Quality of Life Index 
 
  
174 
 
 
  
175 
 
 
  
176 
 
 
 
 
